A	O
logic	O
-	O
based	O
method	O
to	O
build	O
signaling	O
networks	O
and	O
propose	O
experimental	O
plans	O

With	O
the	O
dramatic	O
increase	O
of	O
the	O
diversity	O
and	O
the	O
sheer	O
quantity	O
of	O
biological	O
data	O
generated	O
,	O
the	O
construction	O
of	O
comprehensive	O
signaling	O
networks	O
that	O
include	O
precise	O
mechanisms	O
cannot	O
be	O
carried	O
out	O
manually	O
anymore	O
.	O

In	O
this	O
context	O
,	O
we	O
propose	O
a	O
logic	O
-	O
based	O
method	O
that	O
allows	O
building	O
large	O
signaling	O
networks	O
automatically	O
.	O

Our	O
method	O
is	O
based	O
on	O
a	O
set	O
of	O
expert	O
rules	O
that	O
make	O
explicit	O
the	O
reasoning	O
made	O
by	O
biologists	O
when	O
interpreting	O
experimental	O
results	O
coming	O
from	O
a	O
wide	O
variety	O
of	O
experiment	O
types	O
.	O

These	O
rules	O
allow	O
formulating	O
all	O
the	O
conclusions	O
that	O
can	O
be	O
inferred	O
from	O
a	O
set	O
of	O
experimental	O
results	O
,	O
and	O
thus	O
building	O
all	O
the	O
possible	O
networks	O
that	O
explain	O
these	O
results	O
.	O

Moreover	O
,	O
given	O
an	O
hypothesis	O
,	O
our	O
system	O
proposes	O
experimental	O
plans	O
to	O
carry	O
out	O
in	O
order	O
to	O
validate	O
or	O
invalidate	O
it	O
.	O

To	O
evaluate	O
the	O
performance	O
of	O
our	O
method	O
,	O
we	O
applied	O
our	O
framework	O
to	O
the	O
reconstruction	O
of	O
the	O
FSHR	B-GP
-	O
induced	O
and	O
the	O
EGFR	B-GP
-	O
induced	O
signaling	O
networks	O
.	O

The	O
FSHR	B-GP
is	O
known	O
to	O
induce	O
the	O
transactivation	O
of	O
the	O
EGFR	B-GP
,	O
but	O
very	O
little	O
is	O
known	O
on	O
the	O
resulting	O
FSH	B-GP
-	O
and	O
EGF	B-GP
-	O
dependent	O
network	O
.	O

We	O
built	O
a	O
single	O
network	O
using	O
data	O
underlying	O
both	O
networks	O
.	O

This	O
leads	O
to	O
a	O
new	O
hypothesis	O
on	O
the	O
activation	O
of	O
MEK	B-GP
by	O
p38MAPK	B-GP
,	O
which	O
we	O
validate	O
experimentally	O
.	O

These	O
preliminary	O
results	O
represent	O
a	O
first	O
step	O
in	O
the	O
demonstration	O
of	O
a	O
cross	O
-	O
talk	O
between	O
these	O
two	O
major	O
MAP	B-GP
kinases	I-GP
pathways	O
.	O

Introduction	O

Within	O
a	O
multicellular	O
organism	O
,	O
the	O
behavior	O
of	O
individual	O
cells	O
is	O
partly	O
controlled	O
by	O
hormones	O
that	O
bind	O
to	O
their	O
cognate	O
receptors	O
.	O

Binding	O
of	O
the	O
ligand	O
triggers	O
conformational	O
changes	O
of	O
the	O
receptor	O
’	O
s	O
spatial	O
structure	O
,	O
resulting	O
in	O
the	O
increase	O
or	O
decrease	O
of	O
its	O
affinity	O
for	O
intracellular	O
partners	O
.	O

In	O
the	O
case	O
of	O
G	B-GP
protein	I-GP
-	I-GP
coupled	I-GP
receptors	I-GP
(	O
GPCRs	B-GP
),	O
binding	O
of	O
the	O
extracellular	O
ligand	O
and	O
resulting	O
conformational	O
changes	O
lead	O
to	O
the	O
binding	O
of	O
G	B-GP
proteins	I-GP
and	O
β	B-GP
-	I-GP
arrestins	I-GP
to	O
the	O
intracellular	O
domains	O
of	O
the	O
receptor	O
.	O

In	O
turn	O
,	O
this	O
leads	O
to	O
a	O
number	O
of	O
intracellular	O
cascades	O
,	O
activating	O
or	O
inhibiting	O
intracellular	O
proteins	O
,	O
such	O
as	O
the	O
ERK	B-GP
cascade	O
.	O

These	O
cascades	O
lead	O
,	O
among	O
other	O
things	O
,	O
to	O
the	O
activation	O
/	O
inhibition	O
of	O
transcription	B-GP
factors	I-GP
that	O
regulate	O
gene	O
transcription	O
,	O
and	O
to	O
the	O
activation	O
/	O
inhibition	O
of	O
proteins	O
of	O
the	O
translation	O
machinery	O
.	O

Deciphering	O
these	O
networks	O
is	O
done	O
through	O
numerous	O
wet	O
-	O
lab	O
experiments	O
,	O
and	O
in	O
particular	O
the	O
observation	O
of	O
protein	O
phosphorylation	O
,	O
which	O
plays	O
a	O
major	O
role	O
.	O

The	O
representation	O
of	O
these	O
networks	O
is	O
a	O
diagram	O
,	O
usually	O
referred	O
to	O
as	O
the	O
influence	O
graph	O
.	O

As	O
our	O
knowledge	O
of	O
the	O
complexity	O
of	O
signaling	O
pathways	O
has	O
increased	O
,	O
the	O
influence	O
graphs	O
representing	O
them	O
have	O
also	O
grown	O
in	O
size	O
and	O
complexity	O
.	O

During	O
the	O
past	O
decade	O
,	O
the	O
development	O
of	O
Systems	O
Biology	O
has	O
led	O
to	O
comprehensive	O
reconstructions	O
of	O
large	O
signaling	O
pathways	O
,	O
by	O
gathering	O
results	O
found	O
in	O
the	O
literature1	O
–	O
4	O
.	O

These	O
reconstructed	O
pathways	O
have	O
two	O
particularities	O
as	O
compared	O
to	O
diagrams	O
found	O
earlier	O
in	O
the	O
literature	O
.	O

First	O
,	O
rather	O
than	O
simply	O
depicting	O
influences	O
of	O
molecules	O
on	O
each	O
other	O
(	O
e	O
.	O
g	O
.	O
A	O
activates	O
B	O
),	O
these	O
pathways	O
are	O
detailed	O
representations	O
of	O
the	O
molecular	O
mechanisms	O
that	O
come	O
into	O
play	O
(	O
e	O
.	O
g	O
.	O
A	O
phosphorylates	O
B	O
,	O
and	O
phosphorylated	O
B	O
is	O
active	O
).	O

Second	O
,	O
these	O
pathways	O
are	O
now	O
represented	O
using	O
standards	O
,	O
such	O
as	O
the	O
Systems	O
Biology	O
Graphical	O
Notation	O
(	O
SBGN	O
)	O
Process	O
Description	O
language5	O
(	O
PD	O
),	O
which	O
helps	O
their	O
understanding6	O
.	O

The	O
construction	O
of	O
such	O
comprehensive	O
networks	O
has	O
become	O
difficult	O
due	O
to	O
the	O
ever	O
-	O
growing	O
amount	O
of	O
biological	O
data	O
and	O
experimental	O
results	O
.	O

Moreover	O
,	O
these	O
networks	O
are	O
usually	O
not	O
updated	O
with	O
new	O
findings	O
,	O
due	O
to	O
the	O
cost	O
of	O
these	O
updates	O
.	O

Consequently	O
,	O
automated	O
methods	O
to	O
build	O
such	O
networks	O
are	O
highly	O
needed	O
.	O

Some	O
methods	O
that	O
automatically	O
build	O
molecular	O
networks	O
have	O
already	O
been	O
proposed	O
.	O

A	O
first	O
class	O
of	O
methods	O
relies	O
on	O
literature	O
mining7	O
–	O
9	O
.	O

These	O
methods	O
use	O
Natural	O
Language	O
Processing	O
techniques	O
to	O
extract	O
relevant	O
relationships	O
between	O
molecules	O
(	O
such	O
as	O
“	O
A	O
influences	O
the	O
phosphorylation	O
of	O
B	O
”)	O
from	O
scientific	O
papers	O
,	O
either	O
abstracts7	O
or	O
main	O
text8	O
,	O
9	O
.	O

These	O
extracted	O
relationships	O
are	O
used	O
to	O
build	O
a	O
molecular	O
network	O
.	O

These	O
methods	O
allow	O
building	O
comprehensive	O
networks	O
taking	O
into	O
account	O
the	O
vast	O
amount	O
of	O
available	O
literature	O
;	O
however	O
,	O
they	O
do	O
not	O
permit	O
to	O
infer	O
new	O
unknown	O
relationships	O
.	O

Other	O
methods	O
build	O
networks	O
directly	O
from	O
experimental	O
data10	O
–	O
12	O
.	O

A	O
number	O
of	O
these	O
methods	O
use	O
statistical	O
inference	O
(	O
e	O
.	O
g	O
.	O
co	O
-	O
expression	O
analysis	O
,	O
Bayesian	O
analysis	O
)	O
to	O
build	O
gene	O
networks	O
from	O
gene	O
expression	O
data13	O
–	O
16	O
or	O
phosphoproteomic	O
data17	O
–	O
19	O
.	O

Such	O
techniques	O
are	O
powerful	O
to	O
unveil	O
new	O
relationships	O
hidden	O
deep	O
in	O
the	O
data	O
.	O

However	O
,	O
they	O
function	O
as	O
black	O
boxes	O
,	O
and	O
do	O
not	O
allow	O
to	O
identify	O
the	O
precise	O
data	O
used	O
to	O
build	O
a	O
given	O
relation	O
.	O

Finally	O
,	O
a	O
third	O
category	O
,	O
relying	O
on	O
the	O
use	O
of	O
experimental	O
data	O
,	O
adopts	O
a	O
radically	O
different	O
point	O
of	O
view	O
,	O
by	O
using	O
reasoning	O
techniques	O
to	O
interpret	O
qualitative	O
data20	O
,	O
21	O
.	O

Those	O
methods	O
define	O
expert	O
rules	O
that	O
allow	O
interpreting	O
experimental	O
data	O
in	O
order	O
to	O
build	O
gene	O
regulatory	O
networks20	O
or	O
executable	O
models	O
of	O
signaling	O
pathways21	O
.	O

These	O
models	O
are	O
reaction	O
networks	O
,	O
as	O
they	O
model	O
different	O
molecular	O
processes	O
(	O
e	O
.	O
g	O
.	O
translocations	O
,	O
state	O
transition	O
processes	O
).	O

However	O
,	O
again	O
,	O
the	O
precise	O
biological	O
knowledge	O
underlying	O
a	O
given	O
inferred	O
relation	O
remains	O
implicit22	O
.	O

Hence	O
,	O
such	O
an	O
inference	O
method21	O
does	O
not	O
aim	O
at	O
building	O
molecular	O
networks	O
that	O
could	O
then	O
be	O
interpreted	O
using	O
different	O
semantics	O
(	O
e	O
.	O
g	O
.	O
Ordinary	O
Differential	O
Equations	O
(	O
ODE	O
)),	O
but	O
rather	O
at	O
building	O
models	O
that	O
already	O
carry	O
a	O
modeling	O
semantics	O
.	O

Another	O
current	O
limitation	O
of	O
this	O
method	O
is	O
the	O
lack	O
of	O
rules	O
to	O
infer	O
relationships	O
from	O
perturbation	O
experiments	O
(	O
such	O
as	O
those	O
involving	O
inhibitors	O
,	O
siRNA	O
,	O
knock	O
-	O
outs	O
or	O
mutants	O
),	O
which	O
are	O
widely	O
used	O
in	O
signaling	O
biology	O
.	O

Herein	O
,	O
we	O
introduce	O
a	O
new	O
logic	O
-	O
based	O
method	O
to	O
build	O
networks	O
of	O
biochemical	O
reactions	O
from	O
raw	O
experimental	O
results	O
.	O

We	O
have	O
built	O
a	O
large	O
set	O
of	O
interpretative	O
logic	O
rules	O
that	O
allow	O
mimicking	O
the	O
reasoning	O
biologists	O
apply	O
when	O
interpreting	O
experimental	O
results	O
.	O

Our	O
expert	O
rules	O
are	O
formalized	O
within	O
first	O
-	O
order	O
logic	O
,	O
which	O
allows	O
to	O
capture	O
the	O
deductive	O
nature	O
of	O
the	O
expert	O
’	O
s	O
reasoning	O
using	O
logical	O
implication	O
.	O

Moreover	O
,	O
this	O
formalism	O
is	O
expressive	O
enough	O
to	O
formalize	O
this	O
reasoning	O
as	O
far	O
as	O
it	O
allows	O
general	O
rules	O
to	O
be	O
instantiated	O
in	O
several	O
ways	O
.	O

These	O
rules	O
allow	O
inferring	O
precise	O
biochemical	O
mechanisms	O
from	O
a	O
wide	O
variety	O
of	O
experiments	O
,	O
including	O
perturbation	O
experiments	O
.	O

They	O
also	O
allow	O
formulating	O
new	O
hypothetical	O
relations	O
that	O
can	O
then	O
be	O
tested	O
experimentally	O
.	O

Using	O
explicit	O
rules	O
,	O
traces	O
of	O
the	O
reasoning	O
used	O
for	O
the	O
inference	O
can	O
be	O
obtained	O
.	O

Meaning	O
that	O
for	O
any	O
relation	O
within	O
the	O
inferred	O
network	O
,	O
the	O
set	O
of	O
experimental	O
data	O
and	O
rules	O
used	O
to	O
build	O
this	O
relation	O
can	O
be	O
consulted	O
by	O
the	O
expert	O
.	O

Those	O
are	O
of	O
particular	O
importance	O
when	O
two	O
potentially	O
contradictory	O
pieces	O
of	O
knowledge	O
are	O
inferred	O
,	O
as	O
these	O
originate	O
from	O
contradictory	O
experimental	O
results	O
.	O

In	O
that	O
case	O
,	O
the	O
user	O
is	O
able	O
to	O
go	O
back	O
to	O
these	O
experimental	O
results	O
,	O
and	O
either	O
resolve	O
the	O
contradiction	O
,	O
or	O
choose	O
to	O
ignore	O
some	O
.	O

Finally	O
,	O
rules	O
were	O
built	O
such	O
that	O
the	O
inference	O
process	O
can	O
be	O
inverted	O
,	O
unveiling	O
an	O
unprecedented	O
feature	O
:	O
the	O
automatic	O
proposition	O
of	O
experimental	O
plans	O
to	O
test	O
given	O
biological	O
hypotheses	O
.	O

We	O
illustrate	O
our	O
method	O
by	O
building	O
the	O
signaling	O
networks	O
triggered	O
by	O
the	O
folliculo	B-GP
-	I-GP
stimulating	I-GP
hormone	I-GP
receptor	I-GP
(	O
FSHR	B-GP
)	O
and	O
the	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
(	O
EGFR	B-GP
).	O

Given	O
that	O
the	O
binding	O
of	O
the	O
follicle	B-GP
stimulating	I-GP
hormone	I-GP
(	O
FSH	B-GP
)	O
to	O
its	O
receptor	O
is	O
known	O
to	O
transactivate	O
the	O
EGFR	B-GP
,	O
we	O
also	O
deduce	O
an	O
integrated	O
network	O
from	O
experiments	O
conducted	O
in	O
the	O
study	O
of	O
both	O
individual	O
networks	O
.	O

This	O
led	O
us	O
to	O
the	O
hypothesis	O
that	O
,	O
as	O
a	O
result	O
of	O
FSH	B-GP
stimulation	O
,	O
p38	B-GP
mitogen	I-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
(	O
p38MAPK	B-GP
)	O
activates	O
dual	B-GP
specificity	I-GP
mitogen	I-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
kinase	I-GP
(	O
MEK	B-GP
),	O
through	O
the	O
transactivation	O
of	O
EGFR	B-GP
.	O

We	O
give	O
first	O
experimental	O
evidences	O
that	O
validate	O
this	O
hypothesis	O
.	O

Results	O
and	O
Discussion	O

Explicit	O
interpretative	O
rules	O

Systems	O
Biology	O
mostly	O
focuses	O
on	O
mechanisms	O
:	O
reactions	O
(	O
e	O
.	O
g	O
.	O
post	O
-	O
translational	O
modifications	O
,	O
complexations	O
)	O
and	O
modulations	O
(	O
e	O
.	O
g	O
.	O
catalyzes	O
,	O
inhibitions	O
)	O
of	O
these	O
reactions	O
.	O

This	O
knowledge	O
is	O
usually	O
represented	O
under	O
the	O
form	O
of	O
graphs	O
,	O
where	O
nodes	O
represent	O
the	O
involved	O
molecules	O
,	O
and	O
arcs	O
represent	O
reactions	O
and	O
modulations	O
.	O

Biologists	O
use	O
implicit	O
deductive	O
reasoning	O
to	O
infer	O
new	O
biological	O
knowledge	O
from	O
experimental	O
results	O
,	O
thus	O
interpreting	O
them	O
.	O

The	O
implicit	O
deductive	O
rules	O
with	O
which	O
they	O
reason	O
follow	O
the	O
generic	O
framework	O
:	O
R1	O
\	O
documentclass	O
[	O
12pt	O
]{	O
minimal	O
}	O
\	O
usepackage	O
{	O
amsmath	O
}	O
\	O
usepackage	O
{	O
wasysym	O
}	O
\	O
usepackage	O
{	O
amsfonts	O
}	O
\	O
usepackage	O
{	O
amssymb	O
}	O
\	O
usepackage	O
{	O
amsbsy	O
}	O
\	O
usepackage	O
{	O
mathrsfs	O
}	O
\	O
usepackage	O
{	O
upgreek	O
}	O
\	O
setlength	O
{\	O
oddsidemargin	O
}{-	O
69pt	O
}	O
\	O
begin	O
{	O
document	O
}$$\	O
begin	O
{	O
array	O
}{	O
c	O
}\,{\	O
rm	O
{	O
IF	O
}}\,{\	O
rm	O
{	O
an	O
}}\,	O
experimental	O
\,	O
result	O
\,{\	O
rm	O
{	O
is	O
}}\,{\	O
rm	O
{	O
observed	O
}}\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{\	O
rm	O
{	O
some	O
}}\,	O
pieces	O
\,	O
of	O
\,	O
biological	O
\,	O
knowledge	O
\,{\	O
rm	O
{	O
hold	O
}}\\	O
{\	O
rm	O
{	O
THEN	O
}}\,{\	O
rm	O
{	O
new	O
}}\,	O
pieces	O
\,	O
of	O
\,	O
biological	O
\,	O
knowledge	O
\,{\	O
rm	O
{	O
are	O
}}\,{\	O
rm	O
{	O
established	O
}}\,{\	O
rm	O
{	O
or	O
}}\,{\	O
rm	O
{	O
hypothesized	O
}}\	O
end	O
{	O
array	O
}$$\	O
end	O
{	O
document	O
}	O
IFanexperimentalresultisobservedandsomepiecesofbiologicalknowledgeholdTHENnewpiecesofbiologicalknowledgeareestablishedorhypothesized	O

Those	O
rules	O
are	O
general	O
.	O

Of	O
course	O
,	O
a	O
specific	O
experimental	O
result	O
will	O
lead	O
to	O
a	O
specific	O
interpretation	O
,	O
i	O
.	O
e	O
.	O
to	O
an	O
instantiated	O
piece	O
of	O
biological	O
knowledge	O
,	O
but	O
the	O
manner	O
wherewith	O
it	O
is	O
interpreted	O
does	O
not	O
depend	O
on	O
this	O
particular	O
result	O
.	O

Hence	O
rules	O
in	O
the	O
form	O
of	O
(	O
R1	O
)	O
do	O
not	O
apply	O
only	O
to	O
a	O
particular	O
realization	O
of	O
an	O
experiment	O
but	O
rather	O
to	O
some	O
type	O
of	O
experiment	O
,	O
and	O
it	O
is	O
possible	O
to	O
make	O
explicit	O
the	O
general	O
rules	O
used	O
to	O
interpret	O
results	O
obtained	O
from	O
various	O
types	O
of	O
experiments	O
in	O
order	O
to	O
automate	O
the	O
construction	O
of	O
signaling	O
networks	O
.	O

Building	O
the	O
rules	O

For	O
a	O
given	O
experiment	O
type	O
,	O
we	O
have	O
built	O
one	O
or	O
more	O
interpretative	O
rules	O
by	O
deciphering	O
the	O
molecular	O
processes	O
that	O
come	O
into	O
play	O
while	O
undertaking	O
this	O
experiment	O
.	O

Let	O
us	O
consider	O
a	O
simple	O
phosphorylation	O
assay	O
.	O

In	O
that	O
type	O
of	O
experiment	O
,	O
the	O
quantity	O
of	O
a	O
given	O
target	O
phosphorylated	O
molecule	O
(	O
e	O
.	O
g	O
.	O
phosphorylated	O
extracellular	B-GP
signal	I-GP
-	I-GP
regulated	I-GP
kinase	I-GP
(	O
phospho	O
-	O
ERK	B-GP
))	O
is	O
compared	O
between	O
a	O
cell	O
lysate	O
obtained	O
from	O
untreated	O
cells	O
(	O
the	O
control	O
),	O
and	O
a	O
cell	O
lysate	O
obtained	O
from	O
cells	O
previously	O
treated	O
with	O
a	O
signal	O
(	O
e	O
.	O
g	O
.	O
an	O
hormone	O
such	O
as	O
FSH	B-GP
).	O

The	O
measurement	O
of	O
the	O
quantity	O
of	O
the	O
target	O
molecule	O
may	O
be	O
carried	O
out	O
by	O
means	O
of	O
an	O
antibody	O
specific	O
to	O
the	O
given	O
phosphorylation	O
or	O
incorporation	O
of	O
radioactive	O
phosphate	O
for	O
example	O
.	O

The	O
only	O
molecular	O
process	O
that	O
comes	O
into	O
play	O
here	O
is	O
the	O
production	O
of	O
the	O
target	O
molecule	O
from	O
another	O
form	O
of	O
that	O
molecule	O
(	O
e	O
.	O
g	O
.	O
phospho	O
-	O
ERK	B-GP
is	O
produced	O
by	O
the	O
phosphorylation	O
of	O
ERK	B-GP
),	O
which	O
is	O
known	O
to	O
the	O
experimenter	O
.	O

Hence	O
,	O
if	O
ERK	B-GP
is	O
more	O
phosphorylated	O
in	O
the	O
presence	O
of	O
FSH	B-GP
as	O
compared	O
to	O
the	O
control	O
,	O
we	O
can	O
conclude	O
that	O
FSH	B-GP
stimulates	O
the	O
phosphorylation	O
of	O
ERK	B-GP
.	O

Of	O
course	O
,	O
it	O
doesn	O
’	O
t	O
mean	O
that	O
this	O
modulation	O
is	O
direct	O
.	O

Conversely	O
,	O
if	O
the	O
phosphorylation	O
of	O
ERK	B-GP
was	O
weaker	O
,	O
we	O
would	O
conclude	O
that	O
FSH	B-GP
inhibits	O
the	O
phosphorylation	O
.	O

Finally	O
,	O
if	O
the	O
phosphorylation	O
levels	O
were	O
identical	O
in	O
both	O
conditions	O
,	O
we	O
would	O
conclude	O
that	O
FSH	B-GP
has	O
no	O
effect	O
on	O
the	O
reaction	O
.	O

An	O
experimental	O
result	O
obtained	O
from	O
such	O
an	O
experiment	O
can	O
be	O
interpreted	O
by	O
means	O
of	O
the	O
following	O
rule	O
,	O
considering	O
that	O
the	O
detector	O
is	O
an	O
antibody	O
,	O
and	O
that	O
a	O
greater	O
quantity	O
of	O
the	O
target	O
molecule	O
was	O
observed	O
in	O
the	O
treated	O
cells	O
than	O
in	O
the	O
control	O
:	O

IF	O
a	O
phosphorylation	O
assay	O
in	O
which	O
the	O
signal	O
is	O
a	O
molecule	O
X	O
,	O
the	O
target	O
molecule	O
Ya	O
being	O
detected	O
by	O
an	O
antibody	O
A	O
and	O
obtained	O
by	O
transformation	O
of	O
a	O
molecule	O
Y	O
,	O
demonstrates	O
a	O
greater	O
quantity	O
of	O
Ya	O
in	O
cells	O
treated	O
by	O
X	O
than	O
in	O
the	O
control	O
cells	O
,	O
THEN	O
X	O
stimulates	O
the	O
process	O
that	O
transforms	O
Y	O
into	O
Ya	O
.	O

This	O
interpretative	O
rule	O
can	O
be	O
formalized	O
in	O
first	O
-	O
order	O
logic	O
as	O
follows	O
:	O
R2	O
\	O
documentclass	O
[	O
12pt	O
]{	O
minimal	O
}	O
\	O
usepackage	O
{	O
amsmath	O
}	O
\	O
usepackage	O
{	O
wasysym	O
}	O
\	O
usepackage	O
{	O
amsfonts	O
}	O
\	O
usepackage	O
{	O
amssymb	O
}	O
\	O
usepackage	O
{	O
amsbsy	O
}	O
\	O
usepackage	O
{	O
mathrsfs	O
}	O
\	O
usepackage	O
{	O
upgreek	O
}	O
\	O
setlength	O
{\	O
oddsidemargin	O
}{-	O
69pt	O
}	O
\	O
begin	O
{	O
document	O
}$$\	O
begin	O
{	O
array	O
}{	O
l	O
}\,{\	O
rm	O
{	O
IF	O
}}\,	O
pa	O
(	O
X	O
,	O
Y	O
,	O
A	O
,	O
increase	O
)\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,	O
antibodyAgainst	O
(	O
A	O
,{	O
Y	O
}^{	O
a	O
})\,	O
and	O
\,{	O
mod	O
}	O
ifiedForm	O
({	O
Y	O
}^{	O
a	O
},	O
Y	O
)\\	O
{\	O
rm	O
{	O
THEN	O
}}\,{	O
modulates	O
}(	O
X	O
,	O
Y	O
,{	O
Y	O
}^{	O
a	O
},	O
increase	O
,	O
unknown	O
,	O
confirmed	O
)\	O
end	O
{	O
array	O
}$$\	O
end	O
{	O
document	O
}	O
IFpa	O
(	O
X	O
,	O
Y	O
,	O
A	O
,	O
increase	O
)	O
andantibodyAgainst	O
(	O
A	O
,	O
Ya	O
)	O
andmodifiedForm	O
(	O
Ya	O
,	O
Y	O
)	O
THENmodulates	O
(	O
X	O
,	O
Y	O
,	O
Ya	O
,	O
increase	O
,	O
unknown	O
,	O
confirmed	O
)	O

The	O
left	O
-	O
hand	O
side	O
of	O
the	O
rule	O
(	O
before	O
the	O
“	O
THEN	O
”)	O
is	O
called	O
its	O
premises	O
,	O
while	O
its	O
right	O
-	O
hand	O
side	O
is	O
called	O
its	O
conclusion	O
.	O

The	O
experimental	O
result	O
is	O
expressed	O
in	O
the	O
premises	O
,	O
while	O
its	O
interpretation	O
is	O
given	O
in	O
the	O
conclusion	O
.	O

Such	O
deductive	O
rules	O
should	O
be	O
read	O
as	O
follows	O
:	O
IF	O
the	O
premises	O
hold	O
,	O
THEN	O
the	O
conclusion	O
holds	O
.	O

Lowercase	O
symbols	O
before	O
the	O
opening	O
parenthesis	O
(	O
e	O
.	O
g	O
.	O
pa	O
(	O
phosphorylation	O
assay	O
)	O
or	O
modulates	O
)	O
are	O
predicate	O
symbols	O
that	O
express	O
relations	O
between	O
molecules	O
or	O
parameters	O
.	O

Their	O
arguments	O
(	O
here	O
,	O
variables	O
and	O
constants	O
)	O
are	O
contained	O
between	O
the	O
associated	O
parentheses	O
:	O
lowercase	O
symbols	O
(	O
e	O
.	O
g	O
.	O
increase	O
,	O
confirmed	O
)	O
are	O
constants	O
that	O
refer	O
to	O
molecules	O
or	O
specific	O
parameters	O
,	O
while	O
uppercase	O
symbols	O
(	O
e	O
.	O
g	O
.	O
X	O
,	O
A	O
)	O
are	O
variables	O
that	O
refer	O
to	O
any	O
molecule	O
or	O
parameter	O
value	O
,	O
and	O
can	O
be	O
instantiated	O
by	O
constants	O
.	O

A	O
fully	O
instantiated	O
predicate	O
(	O
i	O
.	O
e	O
.	O
with	O
all	O
its	O
variables	O
replaced	O
by	O
constants	O
),	O
such	O
as	O
modulates	O
(	O
fsh	B-GP
,	O
erk	B-GP
,	O
perk	O
,	O
increase	O
,	O
unknown	O
,	O
confirmed	O
),	O
is	O
called	O
a	O
fact	O
.	O

The	O
predicate	O
symbol	O
modulates	O
takes	O
six	O
arguments	O
,	O
and	O
modulates	O
(	O
X	O
,	O
Y	O
,	O
Ya	O
,	O
E	O
,	O
D	O
,	O
S	O
)	O
qualifies	O
the	O
modulation	O
by	O
molecule	O
X	O
of	O
the	O
process	O
that	O
transforms	O
molecule	O
Y	O
into	O
molecule	O
Ya	O
.	O

The	O
three	O
additional	O
arguments	O
are	O
parameters	O
of	O
this	O
modulation	O
:	O
E	O
is	O
the	O
effect	O
parameter	O
.	O

It	O
stands	O
for	O
the	O
effect	O
of	O
the	O
modulation	O
.	O

It	O
can	O
take	O
three	O
values	O
:	O
increase	O
,	O
decrease	O
,	O
or	O
noeffect	O
,	O
depending	O
on	O
whether	O
the	O
modulation	O
is	O
a	O
stimulation	O
,	O
an	O
inhibition	O
or	O
absent	O
,	O
respectively	O
.	O

This	O
parameter	O
is	O
also	O
an	O
argument	O
of	O
predicates	O
that	O
express	O
experimental	O
results	O
such	O
as	O
pa	O
.	O

For	O
those	O
,	O
increase	O
,	O
decrease	O
and	O
noeffect	O
constants	O
indicate	O
a	O
higher	O
,	O
a	O
lower	O
and	O
an	O
equal	O
quantity	O
of	O
a	O
target	O
molecule	O
in	O
the	O
treated	O
cells	O
than	O
in	O
the	O
control	O
cells	O
,	O
respectively	O
.	O
D	O
is	O
the	O
distance	O
parameter	O
.	O

It	O
stands	O
for	O
the	O
distance	O
with	O
which	O
the	O
modulation	O
takes	O
place	O
:	O
a	O
direct	O
modulation	O
(	O
i	O
.	O
e	O
.	O
with	O
no	O
intermediaries	O
)	O
is	O
represented	O
by	O
the	O
direct	O
constant	O
,	O
and	O
an	O
indirect	O
stimulation	O
by	O
the	O
indirect	O
constant	O
.	O

As	O
for	O
the	O
unknown	O
constant	O
,	O
it	O
indicates	O
that	O
the	O
distance	O
with	O
which	O
the	O
modulation	O
takes	O
place	O
is	O
unknown	O
.	O
S	O
is	O
the	O
status	O
parameter	O
.	O

It	O
can	O
take	O
one	O
of	O
the	O
three	O
values	O
confirmed	O
,	O
hypothesis	O
and	O
infirmed	O
.	O

The	O
confirmed	O
constant	O
indicates	O
that	O
the	O
modulation	O
has	O
been	O
experimentally	O
validated	O
;	O
the	O
hypothesis	O
constant	O
indicates	O
that	O
the	O
modulation	O
is	O
hypothetical	O
,	O
and	O
should	O
be	O
proved	O
by	O
further	O
experiments	O
;	O
and	O
the	O
infirmed	O
constant	O
indicates	O
that	O
the	O
modulation	O
has	O
been	O
experimentally	O
invalidated	O
.	O

Different	O
interpretative	O
rules	O
for	O
different	O
types	O
of	O
experiments	O

Although	O
the	O
number	O
of	O
different	O
experiment	O
types	O
that	O
exist	O
is	O
large	O
,	O
the	O
vast	O
majority	O
of	O
experiments	O
conducted	O
in	O
Systems	O
Biology	O
studies	O
belong	O
to	O
a	O
reduced	O
list	O
.	O

We	O
have	O
gathered	O
28	O
different	O
experiment	O
types	O
that	O
were	O
used	O
to	O
establish	O
a	O
comprehensive	O
map	O
of	O
the	O
FSHR	B-GP
-	O
induced	O
network4	O
.	O

Table	O
1	O
shows	O
the	O
different	O
types	O
of	O
experiments	O
taken	O
into	O
account	O
.	O

A	O
complete	O
description	O
of	O
the	O
various	O
types	O
of	O
experiments	O
is	O
given	O
in	O
Listing	O
of	O
predicates	O
in	O
Supplementary	O
Note	O
.	O
Table	O
1All	O
types	O
of	O
experiments	O
that	O
can	O
be	O
interpreted	O
by	O
the	O
set	O
of	O
expert	O
rules	O
.	O
Type	O
of	O
the	O
conclusionMethodCategoryDisruptorDetection	O
methodExperiment	O
typeExperimental	O
result	O
predicateConceptual	O
experiment	O
type	O
predicateModulationDosageEnzymatic	O
assayRadio25EAea	O
(	O
X	O
,	O
S1	O
,	O
S2	O
,	O
E	O
)	O
simpleEa	O
(	O
X	O
,	O
S1	O
,	O
S2	O
,	O
E	O
)	O
Antagonist50ACPEAacpea	O
(	O
X	O
,	O
S1	O
,	O
S2	O
,	O
I	O
,	O
E	O
)	O
complexEa	O
(	O
X	O
,	O
S1	O
,	O
S2	O
,	O
I	O
,	O
E	O
)	O
Inhibitor50ICPEAicpea	O
(	O
X	O
,	O
S1	O
,	O
S2	O
,	O
I	O
,	O
E	O
)	O
siRNA75SCPEAscpea	O
(	O
X	O
,	O
S1	O
,	O
S2	O
,	O
I	O
,	O
E	O
)	O
Phosphorylation	O
assayAntibody25PApa	O
(	O
X	O
,	O
Y	O
,	O
A	O
,	O
E	O
)	O
simplePa	O
(	O
X	O
,	O
Y	O
,	O
A	O
,	O
E	O
)	O
Radio25PRApra	O
(	O
X	O
,	O
Y	O
,	O
A	O
,	O
E	O
)	O
AntagonistAntibody50ACPPAacppa	O
(	O
X	O
,	O
Y	O
,	O
A	O
,	O
I	O
,	O
E	O
)	O
complexPa	O
(	O
X	O
,	O
Y	O
,	O
A	O
,	O
I	O
,	O
E	O
)	O
Inhibitor50ICPPAicppa	O
(	O
X	O
,	O
Y	O
,	O
A	O
,	O
I	O
,	O
E	O
)	O
Radio50ICPPRAicppra	O
(	O
X	O
,	O
Y	O
,	O
A	O
,	O
I	O
,	O
E	O
)	O
siRNAAntibody75SCPPAscppa	O
(	O
X	O
,	O
Y	O
,	O
A	O
,	O
I	O
,	O
E	O
)	O
ELISAAntibody25ELISAelisa	O
(	O
X	O
,	O
A	O
,	O
E	O
)	O
simpleElisa	O
(	O
X	O
,	O
A	O
,	O
E	O
)	O
Inhibitor50ICELISAicelisa	O
(	O
X	O
,	O
A	O
,	O
I	O
,	O
E	O
)	O
complexElisa	O
(	O
X	O
,	O
A	O
,	O
I	O
,	O
E	O
)	O
siRNA75SCELISAscelisa	O
(	O
X	O
,	O
A	O
,	O
I	O
,	O
E	O
)	O
Radio	O
-	O
immunology	O
ExperimentRadio25RIAria	O
(	O
X	O
,	O
A	O
,	O
E	O
)	O
simpleRia	O
(	O
X	O
,	O
A	O
,	O
E	O
)	O
Inhibitor50ICRIAicria	O
(	O
X	O
,	O
A	O
,	O
I	O
,	O
E	O
)	O
complexRia	O
(	O
X	O
,	O
A	O
,	O
I	O
,	O
E	O
)	O
Western	O
BlotAntibody25WBwb	O
(	O
X	O
,	O
A	O
,	O
E	O
)	O
simpleWb	O
(	O
X	O
,	O
A	O
,	O
E	O
)	O
Inhibitor50ICWBicWb	O
(	O
X	O
,	O
A	O
,	O
E	O
)	O
complexWb	O
(	O
X	O
,	O
A	O
,	O
I	O
,	O
E	O
)	O
75RIWBriWb	O
(	O
X	O
,	O
A	O
,	O
E	O
)	O
QRTPCR25RTPCRqrtpcr	O
(	O
X	O
,	O
Y	O
,	O
E	O
)	O
simpleQrtpcr	O
(	O
X	O
,	O
Y	O
,	O
E	O
)	O
Inhibitor50ICQRTPCRicqrtpcr	O
(	O
X	O
,	O
Y	O
,	O
I	O
,	O
E	O
)	O
complexQrtpcr	O
(	O
X	O
,	O
Y	O
,	O
I	O
,	O
E	O
)	O
InteractionPrecipitationIP25IPip	O
(	O
X	O
,	O
S1	O
)	O
oneToManyInteractionExp	O
(	O
X	O
,	O
S1	O
)	O
PulldownGSTPulldown25GSTPULLDOWNgstPulldown	O
(	O
X	O
,	O
S1	O
)	O
BDPulldown25BDPULLDOWNbdPulldown	O
(	O
X	O
,	O
S1	O
)	O
FRETFRET50FRETfret	O
(	O
X	O
,	O
Y	O
)	O
oneToOneInteractionExp	O
(	O
X	O
,	O
Y	O
)	O
CristallographyCristallography1003DthreeD	O
(	O
S1	O
)	O
manyInteractionExp	O
(	O
S1	O
)	O
PrecipitationIP125IPDipd	O
(	O
X	O
,	O
Y	O
,	O
S1	O
,	O
E	O
)	O
effectOnOneToManyInteractionExp	O
(	O
X	O
,	O
Y	O
,	O
S1	O
,	O
E	O
)	O
LocalizationFluorescence	O
Coloration25FLUO	O
25IHCfluo	O
(	O
A	O
,	O
C	O
,	O
E	O
)	O
ihc	O
(	O
A	O
,	O
C	O
,	O
E	O
)	O
detectionExp	O
(	O
A	O
,	O
C	O
,	O
E	O
)	O
Experiments	O
that	O
can	O
be	O
interpreted	O
by	O
the	O
same	O
general	O
rule	O
have	O
the	O
same	O
color	O
.	O

All	O
these	O
experiments	O
can	O
be	O
classified	O
into	O
three	O
main	O
groups	O
depending	O
on	O
the	O
kind	O
of	O
biological	O
knowledge	O
they	O
allow	O
to	O
deduce	O
(	O
see	O
first	O
column	O
of	O
Table	O
1	O
).	O

All	O
experiment	O
types	O
can	O
be	O
further	O
classified	O
according	O
to	O
different	O
additional	O
criteria	O
,	O
such	O
as	O
the	O
experimental	O
method	O
they	O
bring	O
to	O
play	O
,	O
or	O
the	O
eventual	O
disruptor	O
they	O
use	O
(	O
see	O
Table	O
1	O
for	O
more	O
details	O
).	O

This	O
last	O
criterion	O
allows	O
to	O
distinguish	O
between	O
simple	O
assays	O
(	O
e	O
.	O
g	O
.	O
a	O
phosphorylation	O
assay	O
(	O
pa	O
))	O
and	O
their	O
corresponding	O
complex	O
assays	O
that	O
are	O
realized	O
in	O
presence	O
of	O
a	O
disruptor	O
(	O
e	O
.	O
g	O
.	O
an	O
inhibitor	O
in	O
the	O
case	O
of	O
an	O
icppa	O
).	O

Based	O
on	O
this	O
classification	O
,	O
we	O
generalized	O
the	O
rules	O
related	O
to	O
a	O
number	O
of	O
experiment	O
types	O
taken	O
into	O
account	O
(	O
see	O
Rule	O
generalization	O
in	O
Supplementary	O
Note	O
for	O
some	O
example	O
).	O

In	O
Table	O
1	O
,	O
all	O
the	O
experiment	O
types	O
that	O
can	O
be	O
interpreted	O
by	O
the	O
same	O
general	O
rules	O
have	O
the	O
same	O
color	O
.	O

All	O
the	O
rules	O
are	O
given	O
in	O
Listing	O
of	O
rules	O
in	O
Supplementary	O
Note	O
.	O

Simple	O
and	O
complex	O
interpretative	O
rules	O

In	O
(	O
R2	O
),	O
premises	O
are	O
formed	O
of	O
predicates	O
that	O
cannot	O
be	O
deduced	O
by	O
any	O
other	O
interpretative	O
rule	O
:	O
we	O
call	O
them	O
background	O
knowledge	O
predicates	O
.	O

As	O
for	O
the	O
conclusion	O
,	O
it	O
is	O
formed	O
of	O
a	O
single	O
predicate	O
that	O
provides	O
deduced	O
pieces	O
of	O
knowledge	O
:	O
we	O
call	O
it	O
deduced	O
predicate	O
.	O

We	O
distinguish	O
two	O
kinds	O
of	O
rules	O
,	O
depending	O
on	O
whether	O
they	O
only	O
use	O
background	O
knowledge	O
in	O
their	O
premises	O
,	O
and	O
thus	O
do	O
not	O
require	O
any	O
information	O
deduced	O
from	O
another	O
rule	O
(	O
simple	O
rules	O
),	O
or	O
on	O
the	O
contrary	O
cannot	O
be	O
interpreted	O
in	O
the	O
absence	O
of	O
anterior	O
knowledge	O
(	O
complex	O
rules	O
).	O

Rule	O
(	O
R2	O
)	O
is	O
an	O
example	O
of	O
simple	O
rule	O
.	O

All	O
the	O
rules	O
built	O
to	O
interpret	O
experiments	O
that	O
involve	O
inhibitors	O
or	O
antagonists	O
are	O
examples	O
of	O
complex	O
rules	O
,	O
as	O
they	O
cannot	O
be	O
interpreted	O
without	O
the	O
results	O
of	O
the	O
same	O
experiment	O
conducted	O
without	O
the	O
inhibitor	O
or	O
antagonist	O
.	O

Let	O
us	O
consider	O
the	O
experiment	O
that	O
consists	O
in	O
comparing	O
the	O
phosphorylation	O
of	O
ERK	B-GP
induced	O
by	O
the	O
FSH	B-GP
between	O
untreated	O
cells	O
and	O
cells	O
treated	O
with	O
an	O
inhibitor	O
of	O
protein	B-GP
kinase	I-GP
A	I-GP
(	O
PKA	B-GP
)	O
(	O
for	O
example	O
,	O
with	O
the	O
H89	B-GP
inhibitor23	O
).	O

The	O
result	O
of	O
the	O
experiment	O
is	O
that	O
the	O
phosphorylation	O
of	O
ERK	B-GP
induced	O
by	O
FSH	B-GP
is	O
hampered	O
by	O
the	O
inhibitor	O
,	O
from	O
which	O
an	O
expert	O
can	O
make	O
the	O
hypothesis	O
that	O
PKA	B-GP
might	O
be	O
an	O
intermediary	O
of	O
the	O
activation	O
of	O
ERK	B-GP
by	O
FSH	B-GP
.	O

This	O
type	O
of	O
experiment	O
is	O
called	O
an	O
icppa	O
,	O
and	O
can	O
be	O
interpreted	O
by	O
the	O
following	O
rule	O
when	O
a	O
decrease	O
effect	O
is	O
observed	O
:	O
R3	O
\	O
documentclass	O
[	O
12pt	O
]{	O
minimal	O
}	O
\	O
usepackage	O
{	O
amsmath	O
}	O
\	O
usepackage	O
{	O
wasysym	O
}	O
\	O
usepackage	O
{	O
amsfonts	O
}	O
\	O
usepackage	O
{	O
amssymb	O
}	O
\	O
usepackage	O
{	O
amsbsy	O
}	O
\	O
usepackage	O
{	O
mathrsfs	O
}	O
\	O
usepackage	O
{	O
upgreek	O
}	O
\	O
setlength	O
{\	O
oddsidemargin	O
}{-	O
69pt	O
}	O
\	O
begin	O
{	O
document	O
}$$\	O
begin	O
{	O
array	O
}{	O
c	O
}\,\,{\	O
rm	O
{	O
IF	O
}}\,{	O
iccpa	O
}({	O
X	O
}^{	O
a	O
},	O
Y	O
,	O
A	O
,	O
I	O
,{	O
decrease	O
})\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
antibodyAgainst	O
}(	O
A	O
,{	O
Z	O
}^{	O
a	O
})\,{\	O
rm	O
{	O
and	O
}}\,{	O
inhibitorAgainst	O
}(	O
I	O
,{	O
Y	O
}^{	O
a	O
})\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
modifiedForm	O
}({	O
Y	O
}^{	O
a	O
},	O
Y	O
)\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
notModified	O
}({{	O
X	O
}}^{	O
a	O
})\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
modulates	O
}({	O
X	O
}^{	O
a	O
},	O
Z	O
,{	O
Z	O
}^{	O
a	O
},{	O
increase	O
},{	O
unknown	O
},{	O
confirmed	O
})\\	O
{\	O
rm	O
{	O
THEN	O
}}\,{	O
modulates	O
}({	O
Y	O
}^{	O
a	O
},	O
Z	O
,{	O
Z	O
}^{	O
a	O
},{	O
increase	O
},{	O
unknown	O
},{	O
confirmed	O
})\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
modulates	O
}({	O
X	O
}^{	O
a	O
},	O
Y	O
,{	O
Y	O
}^{	O
a	O
},{	O
increase	O
},{	O
unknown	O
},{	O
hypothesis	O
})\	O
end	O
{	O
array	O
}$$\	O
end	O
{	O
document	O
}	O
IFiccpa	O
(	O
Xa	O
,	O
Y	O
,	O
A	O
,	O
I	O
,	O
decrease	O
)	O
andantibodyAgainst	O
(	O
A	O
,	O
Za	O
)	O
andinhibitorAgainst	O
(	O
I	O
,	O
Ya	O
)	O
andmodifiedForm	O
(	O
Ya	O
,	O
Y	O
)	O
andnotModified	O
(	O
Xa	O
)	O
andmodulates	O
(	O
Xa	O
,	O
Z	O
,	O
Za	O
,	O
increase	O
,	O
unknown	O
,	O
confirmed	O
)	O
THENmodulates	O
(	O
Ya	O
,	O
Z	O
,	O
Za	O
,	O
increase	O
,	O
unknown	O
,	O
confirmed	O
)	O
andmodulates	O
(	O
Xa	O
,	O
Y	O
,	O
Ya	O
,	O
increase	O
,	O
unknown	O
,	O
hypothesis	O
)	O

In	O
this	O
type	O
of	O
experiment	O
,	O
the	O
signal	O
is	O
the	O
molecule	O
Xa	O
(	O
FSH	B-GP
in	O
our	O
example	O
),	O
and	O
the	O
corresponding	O
rule	O
is	O
triggered	O
only	O
if	O
Xa	O
has	O
no	O
modified	O
form	O
,	O
as	O
the	O
predicate	O
notModified	O
(	O
Xa	O
)	O
appears	O
in	O
its	O
premises	O
.	O

Biologically	O
,	O
this	O
means	O
that	O
Xa	O
is	O
not	O
modified	O
in	O
the	O
reaction	O
,	O
which	O
is	O
the	O
case	O
for	O
an	O
extracellular	O
hormone	O
such	O
as	O
FSH	B-GP
,	O
for	O
example	O
.	O

From	O
this	O
type	O
of	O
experiment	O
,	O
we	O
conclude	O
that	O
Ya	O
(	O
activated	O
PKA	B-GP
)	O
stimulates	O
the	O
transformation	O
of	O
Z	O
(	O
ERK	B-GP
)	O
into	O
Za	O
(	O
phospho	O
-	O
ERK	B-GP
),	O
since	O
the	O
quantity	O
of	O
Za	O
is	O
decreased	O
in	O
presence	O
of	O
the	O
inhibitor	O
of	O
Ya	O
(	O
H89	B-GP
).	O

From	O
this	O
first	O
conclusion	O
,	O
two	O
alternatives	O
appear	O
:	O
either	O
Ya	O
can	O
influence	O
Za	O
independently	O
from	O
Xa	O
(	O
activated	O
PKA	B-GP
stimulates	O
the	O
phosphorylation	O
of	O
ERK	B-GP
independently	O
of	O
FSH	B-GP
)	O
and	O
no	O
other	O
additional	O
conclusion	O
has	O
to	O
be	O
made	O
,	O
or	O
Ya	O
is	O
an	O
intermediary	O
of	O
the	O
induction	O
of	O
Za	O
by	O
Xa	O
,	O
meaning	O
that	O
additionally	O
,	O
Xa	O
stimulates	O
the	O
transformation	O
of	O
Y	O
into	O
Ya	O
(	O
FSH	B-GP
stimulates	O
the	O
activation	O
of	O
PKA	B-GP
).	O

As	O
we	O
cannot	O
choose	O
between	O
the	O
two	O
alternatives	O
with	O
only	O
that	O
experiment	O
,	O
both	O
are	O
considered	O
as	O
hypothetical	O
until	O
further	O
confirmation	O
,	O
hence	O
the	O
hypothesis	O
status	O
for	O
the	O
additional	O
conclusion	O
of	O
the	O
second	O
alternative	O
.	O

The	O
following	O
rule	O
allows	O
interpreting	O
the	O
same	O
type	O
of	O
experiment	O
,	O
but	O
leaving	O
the	O
possibility	O
that	O
Xa	O
is	O
the	O
modified	O
form	O
of	O
its	O
inactive	O
counterpart	O
X	O
:	O
R4	O
\	O
documentclass	O
[	O
12pt	O
]{	O
minimal	O
}	O
\	O
usepackage	O
{	O
amsmath	O
}	O
\	O
usepackage	O
{	O
wasysym	O
}	O
\	O
usepackage	O
{	O
amsfonts	O
}	O
\	O
usepackage	O
{	O
amssymb	O
}	O
\	O
usepackage	O
{	O
amsbsy	O
}	O
\	O
usepackage	O
{	O
mathrsfs	O
}	O
\	O
usepackage	O
{	O
upgreek	O
}	O
\	O
setlength	O
{\	O
oddsidemargin	O
}{-	O
69pt	O
}	O
\	O
begin	O
{	O
document	O
}$$\	O
begin	O
{	O
array	O
}{	O
c	O
}\,\,{\	O
rm	O
{	O
IF	O
}}\,{	O
icppa	O
}({	O
X	O
}^{	O
a	O
},	O
Y	O
,	O
A	O
,	O
I	O
,\	O
mathrm	O
{	O
decrease	O
})\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
antibodyAgainst	O
}(	O
A	O
,{	O
Z	O
}^{	O
a	O
})\,{\	O
rm	O
{	O
and	O
}}\,{	O
inhibitorAgainst	O
}(	O
I	O
,{	O
Y	O
}^{	O
a	O
})\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
modifiedForm	O
}({	O
Y	O
}^{	O
a	O
},	O
Y	O
)\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
modifiedForm	O
}({	O
X	O
}^{	O
a	O
},	O
X	O
)\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
modulates	O
}({	O
X	O
}^{	O
a	O
},	O
Z	O
,{	O
Z	O
}^{	O
a	O
},{	O
increase	O
},{	O
unknown	O
},{	O
confirmed	O
})\\	O
{\	O
rm	O
{	O
THEN	O
}}\,{	O
modulates	O
}({	O
Y	O
}^{	O
a	O
},	O
Z	O
,{	O
Z	O
}^{	O
a	O
},{	O
increase	O
},{	O
unknown	O
},{	O
confirmed	O
})\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
modulates	O
}({	O
X	O
}^{	O
a	O
},	O
Y	O
,{	O
Y	O
}^{	O
a	O
},{	O
increase	O
},{	O
unknown	O
},{	O
hypothesis	O
})\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
modulates	O
}({	O
Y	O
}^{	O
a	O
},	O
X	O
,{	O
X	O
}^{	O
a	O
},{	O
increase	O
},{	O
unknown	O
},{	O
hypothesis	O
})\	O
end	O
{	O
array	O
}$$\	O
end	O
{	O
document	O
}	O
IFicppa	O
(	O
Xa	O
,	O
Y	O
,	O
A	O
,	O
I	O
,	O
decrease	O
)	O
andantibodyAgainst	O
(	O
A	O
,	O
Za	O
)	O
andinhibitorAgainst	O
(	O
I	O
,	O
Ya	O
)	O
andmodifiedForm	O
(	O
Ya	O
,	O
Y	O
)	O
andmodifiedForm	O
(	O
Xa	O
,	O
X	O
)	O
andmodulates	O
(	O
Xa	O
,	O
Z	O
,	O
Za	O
,	O
increase	O
,	O
unknown	O
,	O
confirmed	O
)	O
THENmodulates	O
(	O
Ya	O
,	O
Z	O
,	O
Za	O
,	O
increase	O
,	O
unknown	O
,	O
confirmed	O
)	O
andmodulates	O
(	O
Xa	O
,	O
Y	O
,	O
Ya	O
,	O
increase	O
,	O
unknown	O
,	O
hypothesis	O
)	O
andmodulates	O
(	O
Ya	O
,	O
X	O
,	O
Xa	O
,	O
increase	O
,	O
unknown	O
,	O
hypothesis	O
)	O

This	O
rule	O
has	O
one	O
more	O
conclusion	O
compared	O
to	O
rule	O
(	O
R3	O
):\	O
documentclass	O
[	O
12pt	O
]{	O
minimal	O
}	O
\	O
usepackage	O
{	O
amsmath	O
}	O
\	O
usepackage	O
{	O
wasysym	O
}	O
\	O
usepackage	O
{	O
amsfonts	O
}	O
\	O
usepackage	O
{	O
amssymb	O
}	O
\	O
usepackage	O
{	O
amsbsy	O
}	O
\	O
usepackage	O
{	O
mathrsfs	O
}	O
\	O
usepackage	O
{	O
upgreek	O
}	O
\	O
setlength	O
{\	O
oddsidemargin	O
}{-	O
69pt	O
}	O
\	O
begin	O
{	O
document	O
}$${	O
modulates	O
}({	O
Y	O
}^{	O
a	O
},	O
X	O
,{	O
X	O
}^{	O
a	O
},{	O
increase	O
},{	O
unknown	O
},{	O
hypothesis	O
})$$\	O
end	O
{	O
document	O
}	O
modulates	O
(	O
Ya	O
,	O
X	O
,	O
Xa	O
,	O
increase	O
,	O
unknown	O
,	O
hypothesis	O
)	O

The	O
two	O
alternatives	O
given	O
for	O
the	O
case	O
where	O
Xa	O
has	O
no	O
modified	O
form	O
remain	O
valid	O
,	O
but	O
there	O
is	O
a	O
third	O
one	O
:	O
Xa	O
might	O
be	O
an	O
intermediary	O
of	O
the	O
induction	O
of	O
Za	O
by	O
Ya	O
,	O
and	O
thus	O
Ya	O
might	O
stimulate	O
the	O
process	O
that	O
transforms	O
X	O
into	O
Xa	O
.	O

As	O
for	O
the	O
previous	O
case	O
,	O
we	O
cannot	O
rule	O
out	O
any	O
alternative	O
.	O

Figure	O
1	O
shows	O
the	O
interpretation	O
made	O
from	O
an	O
icppa	O
in	O
the	O
case	O
where	O
the	O
signal	O
has	O
as	O
no	O
modified	O
form	O
(	O
top	O
)	O
and	O
in	O
the	O
case	O
where	O
it	O
has	O
one	O
(	O
bottom	O
).	O

For	O
the	O
case	O
where	O
Xa	O
has	O
a	O
modified	O
form	O
,	O
the	O
network	O
on	O
the	O
left	O
represents	O
the	O
alternative	O
where	O
Ya	O
is	O
an	O
intermediary	O
of	O
the	O
induction	O
of	O
Za	O
by	O
Xa	O
,	O
and	O
the	O
network	O
on	O
the	O
right	O
the	O
alternative	O
where	O
it	O
is	O
Xa	O
that	O
is	O
an	O
intermediary	O
between	O
Ya	O
and	O
Za	O
.	O
Figure	O
1Interpretation	O
of	O
a	O
phosphorylation	O
assay	O
with	O
an	O
inhibitor	O
.	O

(	O
A	O
)	O
Case	O
where	O
Xa	O
has	O
no	O
modified	O
form	O
,	O
treated	O
by	O
rule	O
(	O
R3	O
).	O

In	O
the	O
first	O
alternative	O
(	O
left	O
),	O
Ya	O
influences	O
the	O
transformation	O
independently	O
from	O
Xa	O
;	O
in	O
the	O
second	O
alternative	O
(	O
right	O
),	O
Ya	O
is	O
an	O
intermediary	O
of	O
the	O
induction	O
of	O
Za	O
by	O
Xa	O
.	O

(	O
B	O
)	O
Case	O
where	O
Xa	O
has	O
a	O
modified	O
form	O
X	O
,	O
treated	O
by	O
rule	O
(	O
R4	O
).	O

In	O
the	O
first	O
alternative	O
(	O
left	O
),	O
Ya	O
influences	O
the	O
transformation	O
independently	O
from	O
Xa	O
;	O
in	O
the	O
second	O
alternative	O
(	O
middle	O
),	O
Ya	O
is	O
an	O
intermediary	O
of	O
the	O
induction	O
of	O
Za	O
by	O
Xa	O
;	O
in	O
the	O
last	O
alternative	O
(	O
right	O
),	O
Xa	O
is	O
an	O
intermediary	O
of	O
the	O
induction	O
of	O
Za	O
by	O
Ya	O
.	O

For	O
both	O
cases	O
,	O
the	O
confirmed	O
or	O
hypothetical	O
facts	O
that	O
result	O
from	O
the	O
superposition	O
of	O
the	O
different	O
alternatives	O
are	O
represented	O
under	O
the	O
form	O
of	O
a	O
resulting	O
network	O
,	O
on	O
the	O
right	O
of	O
the	O
figure	O
.	O

Blue	O
modulations	O
represent	O
premises	O
,	O
green	O
modulations	O
conclusions	O
that	O
are	O
confirmed	O
,	O
red	O
ones	O
hypotheses	O
,	O
and	O
dashed	O
ones	O
conclusions	O
that	O
could	O
be	O
indirect	O
and	O
explained	O
by	O
transitivity	O
.	O

Analytical	O
rules	O

In	O
addition	O
to	O
interpretative	O
rules	O
,	O
we	O
have	O
built	O
a	O
set	O
of	O
analytical	O
rules	O
that	O
do	O
not	O
interpret	O
any	O
experimental	O
result	O
,	O
but	O
allow	O
to	O
either	O
complete	O
the	O
background	O
knowledge	O
,	O
or	O
to	O
deduce	O
new	O
pieces	O
of	O
knowledge	O
or	O
hypotheses	O
.	O

For	O
example	O
,	O
rule	O
(	O
R5	O
)	O
allows	O
generating	O
an	O
hypothetical	O
modulation	O
based	O
on	O
the	O
distance	O
of	O
already	O
known	O
modulations	O
.	O

Its	O
meaning	O
is	O
the	O
following	O
:	O
if	O
Xa	O
modulates	O
a	O
process	O
that	O
transforms	O
Z	O
into	O
Za	O
,	O
Ya	O
modulates	O
the	O
same	O
process	O
but	O
with	O
a	O
direct	O
distance	O
(	O
i	O
.	O
e	O
.	O
with	O
no	O
intermediary	O
coming	O
into	O
play	O
),	O
and	O
Ya	O
is	O
the	O
modified	O
form	O
of	O
Y	O
,	O
then	O
Xa	O
might	O
modulate	O
the	O
process	O
that	O
transforms	O
Y	O
into	O
Ya	O
.	O
R5	O
\	O
documentclass	O
[	O
12pt	O
]{	O
minimal	O
}	O
\	O
usepackage	O
{	O
amsmath	O
}	O
\	O
usepackage	O
{	O
wasysym	O
}	O
\	O
usepackage	O
{	O
amsfonts	O
}	O
\	O
usepackage	O
{	O
amssymb	O
}	O
\	O
usepackage	O
{	O
amsbsy	O
}	O
\	O
usepackage	O
{	O
mathrsfs	O
}	O
\	O
usepackage	O
{	O
upgreek	O
}	O
\	O
setlength	O
{\	O
oddsidemargin	O
}{-	O
69pt	O
}	O
\	O
begin	O
{	O
document	O
}$$\	O
begin	O
{	O
array	O
}{	O
c	O
}\,\,{\	O
rm	O
{	O
IF	O
}}\,{	O
modulates	O
}({	O
X	O
}^{	O
a	O
},	O
Z	O
,{	O
Z	O
}^{	O
a	O
},{	O
increase	O
},{	O
unknown	O
},{	O
confirmed	O
})\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
modulates	O
}({	O
Y	O
}^{	O
a	O
},	O
Z	O
,{	O
Z	O
}^{	O
a	O
},{	O
increase	O
},{	O
direct	O
},{	O
confirmed	O
})\\	O
\,\,{\	O
rm	O
{	O
and	O
}}\,{	O
modifiedForm	O
}({	O
Y	O
}^{	O
a	O
},	O
Y	O
)\\	O
{\	O
rm	O
{	O
THEN	O
}}\,{	O
modulates	O
}({	O
X	O
}^{	O
a	O
},	O
Y	O
,{	O
Y	O
}^{	O
a	O
},{	O
increase	O
},{	O
unknown	O
},{	O
hypothesis	O
})\	O
end	O
{	O
array	O
}$$\	O
end	O
{	O
document	O
}	O
IFmodulates	O
(	O
Xa	O
,	O
Z	O
,	O
Za	O
,	O
increase	O
,	O
unknown	O
,	O
confirmed	O
)	O
andmodulates	O
(	O
Ya	O
,	O
Z	O
,	O
Za	O
,	O
increase	O
,	O
direct	O
,	O
confirmed	O
)	O
andmodifiedForm	O
(	O
Ya	O
,	O
Y	O
)	O
THENmodulates	O
(	O
Xa	O
,	O
Y	O
,	O
Ya	O
,	O
increase	O
,	O
unknown	O
,	O
hypothesis	O
)	O
Here	O
,	O
we	O
make	O
the	O
hypothesis	O
that	O
Y	O
is	O
an	O
intermediary	O
of	O
the	O
modulation	O
of	O
Z	O
by	O
X	O
.	O

We	O
do	O
not	O
hypothesize	O
that	O
it	O
is	O
X	O
that	O
is	O
an	O
intermediary	O
between	O
Y	O
and	O
Z	O
,	O
since	O
we	O
know	O
that	O
Y	O
has	O
a	O
direct	O
effect	O
on	O
Z	O
.	O

Two	O
tasks	O
:	O
building	O
networks	O
and	O
inferring	O
experimental	O
plans	O

Automated	O
construction	O
of	O
cell	O
signaling	O
networks	O
via	O
deduction	O

The	O
set	O
of	O
interpretative	O
and	O
analytical	O
rules	O
we	O
propose	O
allows	O
establishing	O
automatically	O
new	O
pieces	O
of	O
knowledge	O
from	O
a	O
number	O
of	O
given	O
experimental	O
results	O
.	O

More	O
precisely	O
,	O
given	O
a	O
set	O
of	O
background	O
facts	O
and	O
a	O
set	O
of	O
experimental	O
facts	O
,	O
these	O
rules	O
allow	O
deducing	O
new	O
facts	O
that	O
can	O
then	O
be	O
represented	O
under	O
the	O
form	O
of	O
a	O
signaling	O
network	O
(	O
using	O
the	O
SBGN	O
PD	O
language5	O
for	O
example	O
).	O

A	O
step	O
by	O
step	O
example	O
of	O
such	O
a	O
deductive	O
task	O
is	O
given	O
in	O
Example	O
of	O
deduction	O
in	O
Supplementary	O
Note	O
.	O

By	O
using	O
formal	O
explicit	O
rules	O
and	O
facts	O
,	O
one	O
can	O
track	O
the	O
different	O
deduction	O
steps	O
that	O
lead	O
to	O
a	O
particular	O
fact	O
,	O
in	O
a	O
way	O
that	O
is	O
understandable	O
,	O
and	O
thus	O
verifiable	O
,	O
by	O
the	O
biologist	O
.	O
For	O
a	O
deduced	O
relation	O
,	O
the	O
set	O
of	O
experimental	O
results	O
and	O
rules	O
that	O
enabled	O
its	O
deduction	O
is	O
called	O
its	O
trace	O
.	O

Traces	O
are	O
especially	O
useful	O
when	O
automated	O
reasoning	O
leads	O
to	O
facts	O
that	O
could	O
seem	O
contradictory	O
.	O

For	O
example	O
,	O
two	O
facts	O
,	O
one	O
qualifying	O
the	O
stimulation	O
of	O
a	O
process	O
by	O
a	O
molecule	O
and	O
the	O
other	O
the	O
inhibition	O
of	O
that	O
same	O
process	O
by	O
the	O
same	O
molecule	O
can	O
sometimes	O
be	O
obtained	O
.	O

This	O
is	O
quite	O
possible	O
,	O
for	O
example	O
if	O
two	O
different	O
pathways	O
exist	O
,	O
leading	O
to	O
the	O
same	O
reaction	O
,	O
one	O
being	O
inhibitory	O
and	O
the	O
other	O
activatory	O
.	O

However	O
,	O
experimental	O
results	O
that	O
lead	O
to	O
such	O
a	O
pair	O
of	O
facts	O
should	O
be	O
carefully	O
verified	O
,	O
since	O
they	O
could	O
also	O
result	O
from	O
erroneous	O
experiments	O
.	O

In	O
this	O
case	O
,	O
thanks	O
to	O
traces	O
,	O
our	O
system	O
allows	O
the	O
user	O
going	O
back	O
to	O
these	O
two	O
results	O
,	O
and	O
possibly	O
choosing	O
to	O
ignore	O
one	O
.	O

Automated	O
proposition	O
of	O
experimental	O
plans	O
via	O
abduction	O

Our	O
method	O
also	O
allows	O
to	O
go	O
further	O
.	O

It	O
is	O
often	O
the	O
case	O
that	O
a	O
given	O
molecule	O
or	O
reaction	O
is	O
expected	O
to	O
participate	O
in	O
a	O
given	O
signaling	O
network	O
,	O
and	O
the	O
question	O
then	O
arises	O
of	O
choosing	O
experiments	O
that	O
could	O
validate	O
this	O
hypothesis	O
.	O

Our	O
approach	O
provides	O
a	O
way	O
of	O
answering	O
this	O
question	O
through	O
a	O
method	O
of	O
reasoning	O
called	O
abduction	O
,	O
that	O
can	O
be	O
seen	O
as	O
the	O
inverse	O
process	O
of	O
deduction	O
,	O
and	O
whose	O
goal	O
is	O
to	O
find	O
minimal	O
explanations	O
of	O
an	O
observation	O
,	O
given	O
a	O
background	O
logical	O
theory	O
.	O

In	O
order	O
to	O
check	O
a	O
given	O
biological	O
hypothesis	O
,	O
we	O
first	O
assume	O
that	O
this	O
hypothesis	O
is	O
true	O
,	O
and	O
formalize	O
this	O
assumption	O
by	O
a	O
fact	O
with	O
the	O
status	O
confirmed	O
.	O

Then	O
,	O
using	O
abductive	O
reasoning	O
,	O
we	O
obtain	O
minimal	O
alternative	O
sets	O
of	O
experimental	O
results	O
,	O
each	O
set	O
alone	O
being	O
sufficient	O
to	O
explain	O
the	O
biological	O
fact	O
.	O

The	O
obtained	O
set	O
of	O
inferred	O
experimental	O
results	O
constitutes	O
an	O
experimental	O
plan	O
,	O
that	O
can	O
be	O
carried	O
out	O
in	O
order	O
to	O
test	O
the	O
input	O
hypothesis	O
.	O

A	O
step	O
by	O
step	O
example	O
of	O
such	O
an	O
abductive	O
task	O
is	O
given	O
in	O
Example	O
of	O
abduction	O
in	O
Supplementary	O
Note	O
.	O

Application	O
to	O
the	O
FSHR	B-GP
-	O
induced	O
and	O
the	O
EGFR	B-GP
-	O
induced	O
signaling	O
networks	O

We	O
applied	O
our	O
method	O
to	O
the	O
network	O
induced	O
by	O
the	O
FSHR	B-GP
,	O
and	O
to	O
the	O
network	O
induced	O
by	O
the	O
EGFR	B-GP
.	O

FSH	B-GP
is	O
a	O
pituitary	O
hormone	O
of	O
major	O
importance	O
in	O
the	O
control	O
of	O
male	O
and	O
female	O
reproduction	O
.	O

It	O
acts	O
via	O
its	O
cognate	O
receptor	O
,	O
the	O
FSHR	B-GP
,	O
a	O
Gs	B-GP
-	I-GP
coupled	I-GP
seven	I-GP
transmembrane	I-GP
domain	I-GP
receptor	I-GP
.	O

In	O
females	O
,	O
FSH	B-GP
participates	O
,	O
inter	O
alia	O
,	O
in	O
the	O
induction	O
of	O
ovarian	O
follicles	O
’	O
growth	O
and	O
maturation	O
.	O

In	O
males	O
,	O
it	O
participates	O
in	O
the	O
induction	O
of	O
spermatogenesis	O
by	O
stimulating	O
Sertoli	O
cells	O
.	O

When	O
FSH	B-GP
binds	O
to	O
its	O
receptor	O
,	O
the	O
latter	O
triggers	O
several	O
signaling	O
pathways	O
:	O
the	O
G	O
-	O
dependent	O
pathway	O
,	O
leading	O
to	O
the	O
production	O
of	O
second	O
messenger	O
cyclic	O
AMP	O
(	O
cAMP	O
),	O
but	O
also	O
the	O
phosphatidylinositol	B-GP
-	I-GP
4	I-GP
,	I-GP
5	I-GP
-	I-GP
bisphosphate	I-GP
3	I-GP
-	I-GP
kinase	I-GP
(	O
PI3K	B-GP
)-	O
dependent	O
and	O
β	B-GP
-	I-GP
arrestin	I-GP
-	O
dependent	O
pathways	O
.	O

As	O
for	O
the	O
epidermal	B-GP
growth	I-GP
factor	I-GP
(	O
EGF	B-GP
),	O
it	O
participates	O
in	O
the	O
tissue	O
growth	O
.	O

It	O
acts	O
via	O
its	O
cognate	O
receptor	O
(	O
the	O
EGFR	B-GP
),	O
which	O
belongs	O
to	O
the	O
tyrosine	B-GP
kinase	I-GP
receptors	I-GP
(	O
RTK	B-GP
)	O
family	O
.	O

Activation	O
of	O
EGFR	B-GP
triggers	O
three	O
main	O
signaling	O
pathways	O
:	O
the	O
ERK	B-GP
pathway	O
,	O
the	O
PI3K	B-GP
/	O
protein	B-GP
kinase	I-GP
B	I-GP
(	O
Akt	B-GP
)	O
pathway	O
,	O
and	O
the	O
Jakus	B-GP
kinase	I-GP
(	O
JAK	B-GP
)/	O
signal	B-GP
transducer	I-GP
and	I-GP
activator	I-GP
of	I-GP
transcription	I-GP
protein	I-GP
(	O
STAT	B-GP
)	O
pathway	O
.	O

Finally	O
,	O
these	O
two	O
networks	O
are	O
not	O
independent	O
of	O
each	O
other	O
:	O
the	O
EGFR	B-GP
is	O
transactivated	O
by	O
the	O
FSHR	B-GP
induced	O
network	O
,	O
via	O
the	O
Rous	B-DS
sarcoma	I-DS
oncogene	O
(	O
Src	B-GP
)	O
(	O
see4	O
for	O
a	O
review	O
).	O

We	O
first	O
built	O
the	O
FSHR	B-GP
induced	O
network	O
,	O
by	O
automatically	O
interpreting	O
a	O
set	O
of	O
experimental	O
results	O
linked	O
to	O
this	O
network	O
,	O
which	O
had	O
been	O
used	O
in	O
a	O
previous	O
review4	O
.	O

We	O
then	O
automatically	O
interpreted	O
this	O
set	O
of	O
experimental	O
results	O
by	O
augmenting	O
it	O
with	O
another	O
set	O
of	O
results	O
related	O
to	O
the	O
EGFR	B-GP
induced	O
network	O
.	O

This	O
last	O
interpretation	O
allowed	O
discovering	O
a	O
new	O
hypothesis	O
,	O
for	O
which	O
we	O
subsequently	O
acquired	O
experimental	O
evidence	O
.	O

Retrieving	O
experimental	O
and	O
background	O
knowledge	O
facts	O

The	O
set	O
of	O
experimental	O
and	O
background	O
knowledge	O
facts	O
related	O
to	O
both	O
networks	O
was	O
retrieved	O
from	O
the	O
literature	O
(	O
see	O
Methods	O
for	O
further	O
details	O
).	O

For	O
the	O
FSHR	B-GP
induced	O
network	O
,	O
191	O
experimental	O
results	O
were	O
retrieved	O
,	O
whereas	O
this	O
number	O
reached	O
274	O
for	O
the	O
EGFR	B-GP
induced	O
network	O
.	O

In	O
total	O
,	O
1448	O
background	O
facts	O
were	O
also	O
retrieved	O
for	O
both	O
networks	O
together	O
.	O

Automatic	O
inference	O
of	O
the	O
FSHR	B-GP
induced	O
network	O

We	O
performed	O
the	O
interpretation	O
of	O
the	O
191	O
experimental	O
results	O
related	O
to	O
the	O
FSHR	B-GP
induced	O
network	O
,	O
using	O
the	O
set	O
of	O
expert	O
rules	O
and	O
the	O
set	O
of	O
background	O
knowledge	O
facts	O
.	O

We	O
obtained	O
1535	O
new	O
facts	O
.	O

Among	O
them	O
,	O
1184	O
facts	O
corresponded	O
to	O
background	O
knowledge	O
facts	O
or	O
modulations	O
with	O
a	O
noeffect	O
parameter	O
status	O
.	O

The	O
remaining	O
351	O
pertinent	O
facts	O
(	O
i	O
.	O
e	O
.	O
formalizing	O
a	O
process	O
,	O
the	O
modulation	O
of	O
a	O
process	O
or	O
the	O
localization	O
of	O
a	O
molecule	O
)	O
formed	O
together	O
a	O
molecular	O
network	O
.	O

We	O
compared	O
this	O
network	O
to	O
the	O
FSHR	B-GP
induced	O
network	O
that	O
we	O
previously	O
built	O
manually	O
using	O
the	O
same	O
set	O
of	O
experiments4	O
(	O
see	O
Supplementary	O
Fig	O
.	O
S1	O
for	O
an	O
overview	O
of	O
this	O
network	O
),	O
which	O
will	O
be	O
considered	O
as	O
the	O
reference	O
network	O
.	O

We	O
give	O
an	O
overview	O
of	O
the	O
result	O
of	O
this	O
comparison	O
for	O
the	O
G	B-GP
protein	I-GP
pathway	O
in	O
Comparison	O
for	O
the	O
G	B-GP
protein	I-GP
pathway	O
Supplementary	O
Note	O
.	O

Most	O
differences	O
observed	O
between	O
the	O
two	O
networks	O
can	O
be	O
explained	O
,	O
either	O
by	O
the	O
fact	O
that	O
in	O
graphical	O
representations	O
some	O
details	O
are	O
omitted	O
for	O
the	O
sake	O
of	O
clarity	O
,	O
or	O
by	O
the	O
presence	O
of	O
knowledge	O
in	O
the	O
reference	O
network	O
transferred	O
from	O
other	O
networks	O
,	O
mostly	O
from	O
signaling	O
networks	O
triggered	O
by	O
other	O
GPCRs	B-GP
.	O

This	O
tends	O
to	O
show	O
that	O
our	O
expert	O
rules	O
are	O
complete	O
enough	O
to	O
deduce	O
all	O
the	O
main	O
processes	O
and	O
modulations	O
of	O
a	O
given	O
network	O
.	O

We	O
conducted	O
a	O
similar	O
work	O
on	O
the	O
signaling	O
network	O
of	O
the	O
EGFR	B-GP
(	O
Epidermal	B-GP
Growth	I-GP
Factor	I-GP
Receptor	I-GP
).	O

In	O
that	O
case	O
,	O
our	O
reference	O
was	O
the	O
network	O
of	O
the	O
Pathway	O
Interaction	O
Database	O
(	O
PID	O
)	O
24	O
.	O

Similar	O
to	O
the	O
FSHR	B-GP
case	O
,	O
we	O
extracted	O
the	O
experimental	O
facts	O
from	O
the	O
literature	O
cited	O
in	O
the	O
PID	O
network	O
,	O
and	O
ran	O
the	O
inference	O
.	O

Comparison	O
of	O
the	O
inferred	O
and	O
reference	O
networks	O
showed	O
no	O
significant	O
differences	O
.	O

Discovering	O
a	O
new	O
hypothesis	O
on	O
the	O
phosphorylation	O
of	O
MEK	B-GP
by	O
p38MAPK	B-GP

Because	O
of	O
its	O
complexity	O
,	O
a	O
signaling	O
network	O
is	O
often	O
not	O
studied	O
as	O
a	O
whole	O
,	O
but	O
through	O
the	O
study	O
of	O
individual	O
pathways	O
.	O

However	O
,	O
these	O
different	O
pathways	O
are	O
not	O
independent	O
of	O
each	O
other	O
,	O
and	O
the	O
cellular	O
outcome	O
of	O
the	O
stimulation	O
results	O
from	O
the	O
precise	O
timing	O
and	O
intensity	O
of	O
their	O
activation	O
.	O

Consequently	O
,	O
new	O
knowledge	O
would	O
certainly	O
arise	O
from	O
the	O
study	O
of	O
the	O
complete	O
network	O
,	O
which	O
is	O
possible	O
only	O
through	O
automated	O
modeling	O
.	O

To	O
illustrate	O
this	O
,	O
and	O
because	O
EGFR	B-GP
is	O
known	O
to	O
be	O
transactivated	O
by	O
FSHR	B-GP
,	O
we	O
decided	O
to	O
merge	O
the	O
sets	O
of	O
experimental	O
and	O
background	O
knowledge	O
facts	O
related	O
to	O
the	O
FSHR	B-GP
and	O
the	O
EGFR	B-GP
.	O

We	O
then	O
used	O
our	O
expert	O
rules	O
to	O
deduce	O
new	O
facts	O
from	O
this	O
set	O
.	O

As	O
expected	O
,	O
none	O
of	O
the	O
new	O
deduced	O
facts	O
was	O
obtained	O
by	O
using	O
interpretative	O
rules	O
:	O
indeed	O
,	O
all	O
experimental	O
facts	O
had	O
already	O
been	O
used	O
to	O
deduce	O
facts	O
for	O
each	O
of	O
the	O
two	O
networks	O
.	O

However	O
,	O
rule	O
(	O
R5	O
)	O
allowed	O
generating	O
new	O
hypotheses	O
that	O
were	O
not	O
generated	O
by	O
either	O
of	O
the	O
two	O
sets	O
of	O
experimental	O
results	O
alone	O
.	O

Eleven	O
such	O
new	O
facts	O
were	O
found	O
.	O

Although	O
many	O
of	O
them	O
are	O
not	O
really	O
useful	O
for	O
understanding	O
the	O
biological	O
outcome	O
of	O
the	O
stimulation	O
,	O
one	O
interesting	O
hypothesis	O
emerging	O
from	O
this	O
analysis	O
is	O
that	O
phosphorylated	O
p38MAPK	B-GP
could	O
activate	O
MEK	B-GP
:	O
F1	O
\	O
documentclass	O
[	O
12pt	O
]{	O
minimal	O
}	O
\	O
usepackage	O
{	O
amsmath	O
}	O
\	O
usepackage	O
{	O
wasysym	O
}	O
\	O
usepackage	O
{	O
amsfonts	O
}	O
\	O
usepackage	O
{	O
amssymb	O
}	O
\	O
usepackage	O
{	O
amsbsy	O
}	O
\	O
usepackage	O
{	O
mathrsfs	O
}	O
\	O
usepackage	O
{	O
upgreek	O
}	O
\	O
setlength	O
{\	O
oddsidemargin	O
}{-	O
69pt	O
}	O
\	O
begin	O
{	O
document	O
}$$	O
modulates	O
(	O
pp38mapk	O
,	O
mek	B-GP
,	O
pmek	O
,	O
increase	O
,	O
unknown	O
,	O
hypothesis	O
)$$\	O
end	O
{	O
document	O
}	O
modulates	O
(	O
pp38mapk	O
,	O
mek	B-GP
,	O
pmek	O
,	O
increase	O
,	O
unknown	O
,	O
hypothesis	O
)	O

This	O
hypothesis	O
is	O
deeply	O
interesting	O
for	O
two	O
main	O
reasons	O
.	O

First	O
,	O
p38MAPK	B-GP
is	O
known	O
as	O
the	O
target	O
of	O
stress	O
-	O
activated	O
MAP2K	B-GP
(	O
MAP2K3	B-GP
,	O
MAP2K4	B-GP
and	O
MAP2K6	B-GP
in	O
particular	O
),	O
whereas	O
MEK	B-GP
targets	O
MAPK3	B-GP
(	O
among	O
which	O
ERK	B-GP
)	O
involved	O
in	O
growth	O
.	O

Establishing	O
the	O
existence	O
of	O
a	O
cross	O
-	O
talk	O
between	O
the	O
stress	O
and	O
growth	O
MAPK	B-GP
pathways	O
would	O
show	O
that	O
the	O
two	O
systems	O
are	O
not	O
as	O
insulated	O
as	O
generally	O
thought	O
.	O

Moreover	O
,	O
in	O
signaling	O
cascades	O
,	O
a	O
MAP2K	B-GP
usually	O
activates	O
a	O
MAPK	B-GP
.	O

But	O
here	O
,	O
the	O
hypothesis	O
is	O
that	O
a	O
MAPK	B-GP
(	O
p38	O
)	O
activates	O
a	O
MAP2K	B-GP
(	O
MEK	B-GP
).	O

Second	O
,	O
validating	O
this	O
hypothesis	O
would	O
allow	O
to	O
validate	O
at	O
the	O
same	O
time	O
a	O
number	O
of	O
other	O
hypotheses	O
also	O
generated	O
using	O
rule	O
(	O
R5	O
),	O
that	O
relate	O
to	O
modulations	O
of	O
the	O
phosphorylation	O
of	O
MEK	B-GP
by	O
molecules	O
upstream	O
of	O
phospho	O
-	O
p38MAPK	B-GP
.	O

This	O
gives	O
more	O
weight	O
to	O
such	O
hypotheses	O
,	O
and	O
illustrates	O
one	O
advantage	O
of	O
automatic	O
reasoning	O
:	O
after	O
a	O
small	O
change	O
in	O
the	O
whole	O
theory	O
(	O
here	O
,	O
the	O
addition	O
of	O
a	O
new	O
modulation	O
),	O
new	O
pieces	O
of	O
knowledge	O
that	O
are	O
a	O
consequence	O
of	O
this	O
change	O
can	O
easily	O
be	O
deduced	O
,	O
even	O
if	O
the	O
new	O
pieces	O
of	O
knowledge	O
are	O
located	O
far	O
from	O
where	O
the	O
change	O
is	O
initially	O
made	O
within	O
the	O
network	O
.	O

Experimental	O
plans	O
to	O
establish	O
the	O
phosphorylation	O
of	O
MEK	B-GP
by	O
phospho	O
-	O
p38MAPK	B-GP
in	O
the	O
FSHR	B-GP
system	O

Having	O
deduced	O
the	O
hypothesis	O
that	O
MEK	B-GP
may	O
be	O
phosphorylated	O
by	O
phospho	O
-	O
p38MAPK	B-GP
(	O
fact	O
(	O
F1	O
)),	O
we	O
inferred	O
automatically	O
all	O
experimental	O
plans	O
that	O
would	O
allow	O
validating	O
it	O
.	O

We	O
obtained	O
six	O
different	O
experimental	O
plans	O
,	O
each	O
containing	O
only	O
one	O
experiment	O
to	O
carry	O
out	O
.	O

Those	O
six	O
plans	O
were	O
derived	O
from	O
the	O
following	O
abduced	O
facts	O
:	O
icpea	O
(	O
pmek	O
,	O
s_1_erk1	B-GP
,	O
s_1_perk1	O
,	O
sb203580	O
,	O
decrease	O
)	O
icpea	O
(	O
pmek	O
,	O
s_1_erk2	B-GP
,	O
s_1_perk2	O
,	O
sb203580	O
,	O
decrease	O
)	O
icria	O
(	O
fsh	B-GP
,	O
r_pmek	O
,	O
sb203580	O
,	O
decrease	O
)	O
icelisa	O
(	O
fsh	B-GP
,	O
a_pmek	O
,	O
sb203580	O
,	O
decrease	O
)	O
pa	O
(	O
pp38mapk	O
,	O
mek	B-GP
,	O
a_pmek	O
,	O
increase	O
)	O
icppa	O
(	O
fsh	B-GP
,	O
mek	B-GP
,	O
a_pmek	O
,	O
sb203580	O
,	O
decrease	O
)	O

Experimental	O
plans	O
containing	O
the	O
icria	O
,	O
the	O
icelisa	O
and	O
the	O
icppa	O
predicates	O
proposed	O
to	O
study	O
the	O
effect	O
of	O
an	O
inhibitor	O
of	O
p38MAPK	B-GP
(	O
here	O
,	O
SB203580	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
extremely	O
specific	O
,	O
and	O
has	O
no	O
effect	O
on	O
MEK	B-GP
and	O
ERK	B-GP
activities25	O
)	O
on	O
the	O
stimulation	O
of	O
FSH	B-GP
-	O
triggered	O
MEK	B-GP
phosphorylation	O
using	O
a	O
radio	O
-	O
immunologic	O
assay	O
,	O
a	O
phosphorylation	O
assay	O
or	O
an	O
ELISA	O
,	O
respectively	O
.	O

The	O
two	O
icpea	O
plans	O
proposed	O
to	O
study	O
the	O
effect	O
of	O
the	O
exact	O
same	O
inhibitor	O
on	O
the	O
activity	O
of	O
MEK	B-GP
,	O
through	O
the	O
study	O
in	O
vitro	O
of	O
ERK	B-GP
phosphorylation	O
.	O

Finally	O
,	O
the	O
plan	O
with	O
the	O
pa	O
proposed	O
to	O
test	O
directly	O
the	O
effect	O
of	O
phosphorylated	O
p38MAPK	B-GP
on	O
MEK	B-GP
phosphorylation	O
using	O
a	O
phosphorylation	O
assay	O
.	O

We	O
carried	O
out	O
the	O
simplest	O
plan	O
to	O
implement	O
,	O
which	O
was	O
the	O
icppa	O
.	O

This	O
plan	O
proposed	O
to	O
inhibit	O
p38MAPK	B-GP
and	O
to	O
observe	O
the	O
phosphorylation	O
of	O
MEK	B-GP
in	O
stimulated	O
cells	O
using	O
an	O
antibody	O
specific	O
to	O
the	O
phosphorylated	O
(	O
active	O
)	O
form	O
of	O
MEK	B-GP
,	O
and	O
to	O
compare	O
with	O
activated	O
cells	O
in	O
the	O
absence	O
of	O
the	O
inhibitor	O
.	O

The	O
results	O
(	O
Fig	O
.	O
2	O
)	O
confirm	O
the	O
hypothesis	O
:	O
p38MAPK	B-GP
stimulates	O
the	O
phophorylation	O
of	O
MEK	B-GP
,	O
and	O
through	O
it	O
,	O
the	O
phosphorylation	O
of	O
ERK	B-GP
.	O

Indeed	O
,	O
the	O
phosphorylation	O
level	O
of	O
MEK	B-GP
is	O
significantly	O
lower	O
in	O
the	O
presence	O
of	O
SB203580	O
,	O
an	O
inhibitor	O
of	O
p38MAPK	B-GP
,	O
than	O
in	O
the	O
control	O
conditions	O
.	O

The	O
same	O
phenomenon	O
is	O
observed	O
for	O
the	O
phosphorylation	O
level	O
of	O
ERK	B-GP
.	O
Figure	O
2	O
(	O
A	O
)	O
Levels	O
of	O
MEK	B-GP
and	O
(	O
B	O
)	O
levels	O
of	O
ERK	B-GP
phosphorylation	O
in	O
HEK293	O
cells	O
expressing	O
the	O
FSHR	B-GP
10	O
min	O
after	O
activation	O
by	O
FSH	B-GP
in	O
the	O
presence	O
or	O
absence	O
of	O
SB203580	O
(	O
inhibitor	O
of	O
p38MAPK	B-GP
)	O
and	O
presence	O
or	O
absence	O
of	O
tyrphostin	O
(	O
inhibitor	O
of	O
EGFR	B-GP
).	O

Significant	O
differences	O
are	O
labeled	O
with	O
stars	O
.	O

Results	O
are	O
expressed	O
as	O
the	O
%	O
of	O
the	O
maximum	O
response	O
elicited	O
by	O
FSH	B-GP
in	O
the	O
absence	O
of	O
any	O
inhibitor	O
.	O

(	O
C	O
)	O
The	O
SBGN	O
AF43	O
map	O
representing	O
the	O
different	O
pathways	O
triggered	O
by	O
the	O
FSHR	B-GP
,	O
as	O
well	O
as	O
the	O
transactivation	O
of	O
the	O
EGFR	B-GP
via	O
Src	B-GP
.	O

Our	O
confirmed	O
hypothesis	O
,	O
that	O
p38MAPK	B-GP
stimulates	O
the	O
phosphorylation	O
of	O
MEK	B-GP
,	O
is	O
colored	O
in	O
red	O
.	O

As	O
this	O
hypothesis	O
did	O
not	O
arise	O
from	O
the	O
study	O
of	O
the	O
FSHR	B-GP
signaling	O
network	O
alone	O
,	O
it	O
was	O
also	O
interesting	O
to	O
test	O
whether	O
this	O
modulation	O
arose	O
through	O
the	O
transactivation	O
of	O
EGFR	B-GP
,	O
or	O
was	O
an	O
unknown	O
consequence	O
of	O
the	O
EGFR	B-GP
-	O
independent	O
FSHR	B-GP
signaling	O
pathway	O
.	O

For	O
this	O
purpose	O
we	O
repeated	O
the	O
experiment	O
in	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
the	O
EGFR	B-GP
.	O

Comparing	O
the	O
levels	O
of	O
MEK	B-GP
or	O
ERK	B-GP
phosphorylation	O
in	O
the	O
presence	O
of	O
Tyrphostin	O
,	O
the	O
inhibitor	O
of	O
EGFR	B-GP
,	O
shows	O
a	O
tendency	O
to	O
decrease	O
,	O
but	O
this	O
effect	O
is	O
not	O
significant	O
.	O

Comparing	O
the	O
phosphorylation	O
of	O
ERK	B-GP
is	O
the	O
presence	O
of	O
both	O
Tyrphostin	O
and	O
SB203580	O
shows	O
a	O
significant	O
decrease	O
as	O
compared	O
to	O
control	O
conditions	O
,	O
but	O
also	O
to	O
the	O
conditions	O
with	O
SB203580	O
alone	O
.	O

Moreover	O
,	O
this	O
is	O
not	O
observed	O
for	O
MEK	B-GP
phosphorylation	O
levels	O
.	O

This	O
could	O
mean	O
that	O
there	O
exists	O
a	O
pathway	O
leading	O
to	O
ERK	B-GP
phosphorylation	O
which	O
depends	O
on	O
EGFR	B-GP
(	O
since	O
the	O
effect	O
is	O
decreased	O
in	O
the	O
presence	O
of	O
Tyrphostin	O
),	O
but	O
neither	O
on	O
p38MAPK	B-GP
(	O
since	O
SB203580	O
is	O
present	O
in	O
both	O
conditions	O
),	O
nor	O
on	O
MEK	B-GP
(	O
since	O
the	O
effect	O
is	O
not	O
observed	O
for	O
MEK	B-GP
).	O

However	O
,	O
the	O
observed	O
differences	O
could	O
also	O
be	O
due	O
to	O
technical	O
reasons	O
,	O
such	O
as	O
differences	O
in	O
quality	O
or	O
affinity	O
of	O
the	O
antibodies	O
used	O
to	O
detect	O
the	O
phosphorylated	O
forms	O
of	O
MEK	B-GP
and	O
ERK	B-GP
,	O
or	O
differences	O
in	O
the	O
total	O
amounts	O
of	O
both	O
proteins	O
present	O
in	O
the	O
cells	O
.	O

Drawing	O
more	O
definitive	O
conclusions	O
would	O
require	O
more	O
experiments	O
,	O
using	O
different	O
protocols	O
,	O
which	O
was	O
not	O
the	O
scope	O
of	O
the	O
present	O
paper	O
.	O

From	O
deduced	O
facts	O
to	O
mathematical	O
models	O

The	O
output	O
of	O
our	O
method	O
is	O
a	O
set	O
of	O
logical	O
deduced	O
facts	O
that	O
formalize	O
knowledge	O
on	O
molecular	O
mechanisms	O
,	O
and	O
that	O
form	O
together	O
a	O
molecular	O
network	O
.	O

These	O
facts	O
can	O
easily	O
be	O
translated	O
to	O
standard	O
graphical	O
or	O
textual	O
languages	O
,	O
such	O
as	O
SBGN	O
PD5	O
/	O
SBGN	O
ER26	O
or	O
BioPax27	O
.	O

Also	O
,	O
the	O
output	O
networks	O
represent	O
static	O
knowledge	O
and	O
do	O
not	O
carry	O
any	O
dynamics	O
semantics	O
.	O

Hence	O
,	O
they	O
can	O
be	O
used	O
as	O
inputs	O
for	O
(	O
automatic	O
)	O
mathematical	O
model	O
building	O
under	O
a	O
wide	O
variety	O
of	O
semantics	O
and	O
formalisms	O
,	O
such	O
as	O
the	O
rule	O
-	O
based	O
entity	O
-	O
centered	O
semantics	O
and	O
ODEs9	O
,	O
28	O
,	O
29	O
,	O
plain	O
ODEs30	O
,	O
or	O
qualitative	O
semantics29	O
,	O
31	O
.	O

These	O
mathematical	O
models	O
can	O
in	O
turn	O
be	O
stored	O
and	O
exchanged	O
using	O
standard	O
formats	O
such	O
as	O
the	O
BioNetGen	O
Language	O
format28	O
for	O
rule	O
-	O
based	O
models	O
,	O
or	O
the	O
Systems	O
Biology	O
Markup	O
Language	O
format32	O
for	O
ODEs	O
and	O
qualitative	O
models	O
.	O

Scalability	O
and	O
automation	O

One	O
weakness	O
of	O
our	O
framework	O
that	O
clearly	O
appeared	O
during	O
this	O
work	O
is	O
the	O
manual	O
entry	O
of	O
experimental	O
and	O
background	O
facts	O
.	O

Going	O
through	O
scientific	O
papers	O
to	O
extract	O
experimental	O
results	O
and	O
formating	O
them	O
for	O
the	O
inference	O
engine	O
is	O
a	O
tedious	O
and	O
error	O
-	O
prone	O
task	O
.	O

Consequently	O
,	O
scalability	O
of	O
the	O
method	O
,	O
apart	O
from	O
pure	O
computational	O
aspects	O
,	O
will	O
also	O
need	O
the	O
automation	O
of	O
this	O
extraction	O
and	O
formating	O
task	O
.	O

This	O
led	O
us	O
to	O
start	O
the	O
development	O
of	O
a	O
method	O
,	O
using	O
natural	O
language	O
processing	O
,	O
to	O
automate	O
this	O
task	O
.	O

We	O
have	O
already	O
shown	O
that	O
we	O
can	O
isolate	O
,	O
within	O
a	O
scientific	O
paper	O
,	O
the	O
sentences	O
relative	O
to	O
the	O
results	O
of	O
an	O
experiment33	O
.	O

We	O
are	O
now	O
developing	O
cascades	O
within	O
the	O
CasSys	O
system34	O
to	O
format	O
these	O
experimental	O
results	O
as	O
facts	O
that	O
could	O
be	O
used	O
directly	O
within	O
the	O
framework	O
described	O
in	O
the	O
present	O
paper	O
.	O

The	O
first	O
tests	O
have	O
shown	O
that	O
we	O
were	O
able	O
to	O
extract	O
and	O
format	O
successfully	O
both	O
background	O
and	O
experimental	O
facts	O
with	O
good	O
precision	O
(	O
76	O
%)	O
and	O
recall	O
(	O
88	O
%).	O

This	O
work	O
is	O
still	O
preliminary	O
,	O
and	O
will	O
require	O
many	O
more	O
developments	O
.	O

However	O
,	O
we	O
already	O
have	O
a	O
proof	O
of	O
concept	O
that	O
such	O
automated	O
extraction	O
and	O
formatting	O
of	O
background	O
and	O
experimental	O
facts	O
from	O
literature	O
is	O
feasible	O
using	O
natural	O
language	O
processing	O
.	O

Another	O
question	O
is	O
how	O
scalable	O
is	O
the	O
method	O
?	O

Giving	O
a	O
definitive	O
answer	O
to	O
this	O
question	O
would	O
require	O
a	O
very	O
large	O
dataset	O
of	O
experimental	O
facts	O
,	O
which	O
will	O
be	O
available	O
only	O
after	O
completion	O
of	O
the	O
natural	O
language	O
treatment	O
-	O
based	O
extraction	O
and	O
formatting	O
method	O
.	O

However	O
,	O
the	O
computation	O
times	O
observed	O
during	O
our	O
first	O
tests	O
seem	O
to	O
depend	O
linearly	O
on	O
the	O
number	O
of	O
experimental	O
facts	O
(	O
Table	O
2	O
).	O

Similarly	O
,	O
the	O
number	O
of	O
deduced	O
facts	O
seems	O
to	O
depend	O
linearly	O
on	O
the	O
number	O
of	O
experimental	O
facts	O
.	O

Finally	O
,	O
the	O
computation	O
times	O
are	O
very	O
low	O
,	O
and	O
if	O
the	O
linearity	O
is	O
confirmed	O
,	O
the	O
framework	O
could	O
be	O
applied	O
to	O
very	O
large	O
datasets	O
.	O
Table	O
2Numbers	O
of	O
experimental	O
facts	O
,	O
deduced	O
facts	O
and	O
computation	O
times	O
for	O
the	O
studied	O
networks	O
.	O
NetworkFSHREGFRFSHR	O
+	O
EGFRExperimental	O
facts191274465New	O
facts155224133058Pertinent	O
facts344583993CPU	O
time	O
(	O
s	O
)	O
4	O
.	O
48	O
.	O
712	O
.	O
8	O

Knowledge	O
transfer	O

As	O
discussed	O
above	O
,	O
in	O
the	O
signaling	O
network	O
we	O
built	O
,	O
some	O
relations	O
were	O
missing	O
because	O
they	O
have	O
not	O
been	O
demonstrated	O
in	O
the	O
case	O
of	O
the	O
FSHR	B-GP
and	O
/	O
or	O
the	O
EGFR	B-GP
.	O

However	O
,	O
these	O
relations	O
are	O
considered	O
as	O
true	O
by	O
the	O
experts	O
,	O
either	O
because	O
they	O
have	O
been	O
demonstrated	O
using	O
purified	O
proteins	O
,	O
or	O
because	O
they	O
have	O
been	O
demonstrated	O
for	O
many	O
different	O
conditions	O
.	O

As	O
an	O
example	O
,	O
when	O
we	O
reconstructed	O
the	O
EGFR	B-GP
signaling	O
network	O
,	O
we	O
did	O
not	O
obtain	O
the	O
inhibition	O
relation	O
between	O
Tsc2	B-GP
and	O
Rheb	B-GP
.	O

Indeed	O
,	O
in	O
the	O
scientific	O
paper	O
corpus	O
we	O
have	O
used	O
,	O
this	O
inhibition	O
of	O
Rheb	B-GP
by	O
Tsc2	B-GP
was	O
not	O
demonstrated	O
.	O

We	O
then	O
searched	O
the	O
literature	O
for	O
such	O
a	O
demonstration	O
,	O
but	O
we	O
could	O
not	O
find	O
an	O
experiment	O
demonstrating	O
that	O
EGF	B-GP
-	O
activated	O
Tsc2	B-GP
inhibits	O
Rheb	B-GP
.	O

However	O
,	O
we	O
found	O
many	O
papers	O
demonstrating	O
this	O
inhibition	O
relation	O
,	O
using	O
purified	O
proteins35	O
or	O
in	O
vivo	O
,	O
following	O
different	O
stimulations	O
such	O
as	O
insulin36	B-GP
,	O
ephrin37	B-GP
or	O
tissue	B-GP
plasminogen	I-GP
activator38	I-GP
.	O

More	O
generally	O
,	O
Tsc2	B-GP
has	O
been	O
shown	O
to	O
be	O
an	O
important	O
hub	O
in	O
the	O
signaling	O
pathways	O
triggered	O
by	O
many	O
different	O
signals	O
such	O
as	O
amino	O
acid	O
availability	O
,	O
growth	B-GP
factors	I-GP
,	O
cytokines	B-GP
,	O
and	O
energy39	O
.	O

Thus	O
,	O
in	O
this	O
particular	O
example	O
,	O
it	O
seems	O
reasonable	O
to	O
consider	O
that	O
in	O
the	O
EGFR	B-GP
pathway	O
Rheb	B-GP
is	O
inhibited	O
by	O
Tsc2	B-GP
.	O

This	O
raises	O
the	O
question	O
of	O
transferring	O
knowledge	O
between	O
different	O
networks	O
and	O
/	O
or	O
different	O
biological	O
conditions	O
.	O

The	O
example	O
above	O
is	O
a	O
direct	O
action	O
,	O
demonstrated	O
using	O
purified	O
proteins	O
.	O

In	O
such	O
cases	O
we	O
could	O
consider	O
that	O
in	O
any	O
cell	O
,	O
and	O
under	O
any	O
condition	O
,	O
if	O
the	O
two	O
proteins	O
are	O
present	O
,	O
the	O
conclusion	O
holds	O
.	O

But	O
many	O
possible	O
cases	O
are	O
more	O
difficult	O
to	O
decide	O
than	O
this	O
one	O
.	O

For	O
example	O
,	O
can	O
experimental	O
data	O
obtained	O
in	O
a	O
given	O
cell	O
line	O
be	O
used	O
to	O
build	O
a	O
network	O
in	O
another	O
cell	O
line	O
?	O

Or	O
when	O
the	O
cell	O
lines	O
are	O
the	O
same	O
,	O
but	O
the	O
experimental	O
conditions	O
,	O
such	O
as	O
growth	O
media	O
,	O
are	O
different	O
?	O

These	O
are	O
of	O
course	O
questions	O
that	O
cannot	O
be	O
answered	O
only	O
through	O
computational	O
tools	O
,	O
and	O
it	O
will	O
ultimately	O
be	O
the	O
user	O
’	O
s	O
decision	O
.	O

However	O
,	O
tools	O
can	O
be	O
designed	O
to	O
guide	O
this	O
decision	O
.	O

In	O
our	O
framework	O
the	O
user	O
can	O
always	O
come	O
back	O
to	O
the	O
experimental	O
data	O
used	O
to	O
deduce	O
a	O
given	O
relation	O
.	O

This	O
can	O
be	O
such	O
a	O
guiding	O
element	O
,	O
but	O
more	O
will	O
have	O
to	O
be	O
added	O
in	O
the	O
future	O
.	O

Conclusions	O

In	O
this	O
article	O
,	O
we	O
propose	O
a	O
logic	O
-	O
based	O
method	O
to	O
automate	O
the	O
construction	O
of	O
signaling	O
networks	O
.	O

Our	O
method	O
tries	O
to	O
reproduce	O
the	O
reasoning	O
made	O
by	O
biologists	O
when	O
interpreting	O
experimental	O
results	O
,	O
by	O
automatically	O
deducing	O
new	O
knowledge	O
using	O
a	O
set	O
of	O
expert	O
rules	O
that	O
make	O
explicit	O
this	O
reasoning	O
.	O

These	O
rules	O
allow	O
interpreting	O
experimental	O
results	O
coming	O
from	O
a	O
large	O
variety	O
of	O
experiments	O
that	O
are	O
usually	O
employed	O
in	O
cell	O
signaling	O
,	O
and	O
to	O
infer	O
precise	O
mechanisms	O
,	O
at	O
the	O
molecular	O
reaction	O
scale	O
.	O

Moreover	O
,	O
they	O
allow	O
formulating	O
a	O
number	O
of	O
biological	O
hypotheses	O
,	O
and	O
experimental	O
plans	O
to	O
validate	O
them	O
.	O

Our	O
method	O
allowed	O
us	O
to	O
successfully	O
reconstruct	O
two	O
large	O
networks	O
:	O
the	O
FSH	B-GP
-	O
triggered	O
and	O
the	O
EGF	B-GP
-	O
triggered	O
networks	O
.	O

Using	O
the	O
two	O
sets	O
of	O
underlying	O
data	O
at	O
the	O
same	O
time	O
led	O
us	O
to	O
formulate	O
the	O
hypothesis	O
that	O
p38MAPK	B-GP
would	O
stimulate	O
the	O
phosphorylation	O
of	O
MEK	B-GP
.	O

In	O
order	O
to	O
validate	O
this	O
hypothesis	O
,	O
we	O
automatically	O
inferred	O
an	O
experimental	O
plan	O
using	O
our	O
method	O
,	O
that	O
we	O
have	O
carried	O
out	O
.	O

The	O
results	O
obtained	O
show	O
that	O
p38MAPK	B-GP
stimulates	O
the	O
phosphorylation	O
of	O
MEK	B-GP
in	O
an	O
FSHR	B-GP
-	O
induced	O
system	O
,	O
as	O
MEK	B-GP
activation	O
is	O
significantly	O
lower	O
in	O
the	O
presence	O
of	O
p38MAPK	B-GP
inhibitor	O
.	O

As	O
a	O
consequence	O
,	O
ERK	B-GP
phosphorylation	O
is	O
also	O
decreased	O
when	O
p38MAPK	B-GP
is	O
inhibited	O
.	O

We	O
also	O
observed	O
further	O
inhibition	O
of	O
activity	O
in	O
the	O
presence	O
of	O
the	O
EGFR	B-GP
inhibitor	O
for	O
ERK	B-GP
,	O
but	O
not	O
for	O
MEK	B-GP
.	O

This	O
could	O
be	O
the	O
effect	O
of	O
another	O
activation	O
mechanism	O
of	O
ERK	B-GP
,	O
depending	O
on	O
EGFR	B-GP
transactivation	O
,	O
but	O
not	O
on	O
p38MAPK	B-GP
or	O
MEK	B-GP
.	O

This	O
first	O
experimental	O
validation	O
would	O
need	O
to	O
be	O
consolidated	O
,	O
which	O
is	O
not	O
the	O
object	O
of	O
the	O
present	O
paper	O
.	O

However	O
,	O
it	O
constitutes	O
a	O
first	O
step	O
in	O
the	O
discovery	O
of	O
a	O
yet	O
-	O
unknown	O
cross	O
-	O
talk	O
between	O
these	O
two	O
very	O
important	O
signaling	O
pathways	O
.	O

Although	O
preliminary	O
,	O
these	O
results	O
demonstrate	O
that	O
our	O
method	O
allows	O
to	O
make	O
high	O
-	O
level	O
hypotheses	O
,	O
based	O
on	O
already	O
known	O
facts	O
,	O
and	O
could	O
be	O
an	O
important	O
driving	O
force	O
for	O
understanding	O
the	O
signaling	O
pathways	O
in	O
their	O
complexity	O
.	O

Applying	O
our	O
method	O
to	O
large	O
sets	O
of	O
experimental	O
data	O
could	O
be	O
facilitated	O
by	O
new	O
evolutions	O
,	O
and	O
our	O
efforts	O
will	O
take	O
two	O
directions	O
.	O

First	O
,	O
we	O
need	O
to	O
expand	O
the	O
number	O
of	O
experiments	O
that	O
can	O
be	O
automatically	O
interpreted	O
.	O

In	O
particular	O
,	O
experiments	O
involving	O
the	O
use	O
of	O
mutants	O
(	O
either	O
cells	O
expressing	O
mutant	O
proteins	O
,	O
or	O
even	O
knock	O
-	O
out	O
animals	B-OG
)	O
are	O
often	O
used	O
,	O
but	O
the	O
corresponding	O
rules	O
are	O
delicate	O
to	O
establish	O
,	O
since	O
the	O
driving	O
idea	O
for	O
making	O
a	O
mutation	O
is	O
often	O
implicit	O
.	O

Another	O
important	O
area	O
we	O
have	O
to	O
formalize	O
corresponds	O
to	O
the	O
in	O
vivo	O
experiments	O
.	O

Second	O
,	O
we	O
have	O
to	O
be	O
able	O
to	O
extract	O
the	O
facts	O
automatically	O
from	O
scientific	O
papers	O
.	O

Indeed	O
,	O
manually	O
gathering	O
the	O
relevant	O
literature	O
,	O
extracting	O
the	O
experimental	O
data	O
,	O
and	O
subsequently	O
writing	O
the	O
facts	O
is	O
a	O
tedious	O
task	O
,	O
and	O
consequently	O
limits	O
the	O
applicability	O
of	O
the	O
method	O
.	O

A	O
standard	O
format	O
for	O
reporting	O
experimental	O
results	O
would	O
of	O
course	O
greatly	O
facilitate	O
automated	O
extraction	O
,	O
and	O
the	O
work	O
discussed	O
here	O
could	O
be	O
straightforwardly	O
used	O
to	O
design	O
such	O
a	O
format	O
.	O

However	O
,	O
we	O
do	O
not	O
believe	O
scientific	O
community	O
is	O
ready	O
to	O
format	O
and	O
report	O
experimental	O
results	O
,	O
and	O
not	O
enough	O
results	O
would	O
be	O
gathered	O
by	O
this	O
mean	O
to	O
make	O
the	O
method	O
really	O
powerful	O
.	O

Instead	O
,	O
we	O
are	O
developing	O
a	O
method	O
,	O
based	O
on	O
natural	O
language	O
processing	O
,	O
which	O
should	O
allow	O
to	O
extract	O
and	O
format	O
experimental	O
facts	O
directly	O
from	O
published	O
papers	O
.	O

Methods	O

Retrieving	O
the	O
experimental	O
facts	O

Experimental	O
facts	O
relative	O
to	O
both	O
networks	O
have	O
been	O
manually	O
retrieved	O
from	O
the	O
literature	O
.	O

The	O
corpus	O
of	O
scientific	O
papers	O
considered	O
for	O
FSHR	B-GP
signaling	O
was	O
the	O
exact	O
same	O
one	O
used	O
to	O
build	O
a	O
comprehensive	O
literature	O
network4	O
,	O
so	O
that	O
the	O
inferred	O
network	O
and	O
the	O
literature	O
network	O
could	O
be	O
compared	O
.	O

This	O
corpus	O
was	O
initially	O
assembled	O
by	O
reviewing	O
the	O
literature	O
.	O

As	O
for	O
the	O
corpus	O
of	O
scientific	O
papers	O
considered	O
for	O
EGFR	B-GP
signaling	O
,	O
it	O
has	O
been	O
found	O
in	O
the	O
PID24	O
(	O
data	O
now	O
available	O
through	O
the	O
NDEx	O
database40	O
).	O

Deduction	O
with	O
answer	O
set	O
programming	O

Deduction	O
was	O
performed	O
by	O
means	O
of	O
answer	O
set	O
programming	O
(	O
ASP	O
)	O
using	O
the	O
clingo	O
software41	O
.	O

Our	O
expert	O
rules	O
were	O
straightforwardly	O
translated	O
into	O
ASP	O
rules	O
.	O

The	O
ASP	O
program	O
consists	O
of	O
a	O
set	O
of	O
background	O
knowledge	O
and	O
experimental	O
facts	O
,	O
and	O
the	O
translated	O
expert	O
rules	O
.	O

This	O
program	O
has	O
a	O
unique	O
answer	O
set	O
which	O
is	O
exactly	O
the	O
set	O
of	O
facts	O
that	O
can	O
be	O
deduced	O
from	O
the	O
initial	O
facts	O
and	O
the	O
rules	O
.	O

Traces	O
can	O
be	O
obtained	O
at	O
the	O
same	O
time	O
as	O
sets	O
of	O
deduced	O
facts	O
by	O
using	O
a	O
simple	O
transformation	O
of	O
the	O
ASP	O
rules	O
(	O
see	O
Traces	O
in	O
ASP	O
in	O
Supplementary	O
Note	O
for	O
more	O
details	O
).	O

Computations	O
were	O
made	O
on	O
an	O
Intel	O
(	O
R	O
)	O
Xeon	O
(	O
R	O
)	O
CPU	O
E5	O
-	O
1620v4	O
@	O
3	O
.	O
50	O
GHz	O
.	O

Inference	O
of	O
experimental	O
plans	O
with	O
SOLAR	O

Inference	O
of	O
experimental	O
plans	O
was	O
performed	O
with	O
the	O
software	O
SOLAR42	O
,	O
using	O
abductive	O
reasoning	O
.	O

As	O
for	O
deduction	O
with	O
ASP	O
,	O
the	O
expert	O
rules	O
were	O
straightforwardly	O
translated	O
into	O
SOLAR	O
’	O
s	O
input	O
language	O
.	O

Experimental	O
plans	O
for	O
a	O
given	O
hypothesis	O
were	O
then	O
computed	O
using	O
the	O
negation	O
of	O
the	O
hypothesis	O
as	O
the	O
top	O
clause	O
.	O

Cell	O
Culture	O
and	O
Western	O
-	O
blots	O

Human	B-OG
embryonic	O
kidney	O
(	O
HEK	O
)-	O
293	O
cells	O
stably	O
expressing	O
mFSH	O
-	O
R	O
were	O
cultured	O
in	O
minimum	O
Eagle	O
’	O
s	O
medium	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
and	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
in	O
100	O
-	O
mm	O
dishes	O
.	O

Slow	O
growing	O
early	O
passage	O
(<	O
10	O
)	O
cells	O
were	O
divided	O
into	O
12	O
-	O
well	O
plates	O
and	O
,	O
at	O
50	O
%	O
confluency	O
,	O
serum	O
-	O
starved	O
for	O
4	O
h	O
prior	O
to	O
stimulation	O
.	O

Cells	O
were	O
then	O
incubated	O
with	O
SB203580	O
(	O
10	O
μM	O
,	O
30	O
min	O
)	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
MO	O
),	O
Tyrphostin	O
(	O
10	O
μM	O
,	O
1	O
h	O
)	O
(	O
Sigma	O
)	O
or	O
the	O
combination	O
of	O
the	O
2	O
inhibitors	O
,	O
before	O
stimulation	O
with	O
100	O
ng	O
/	O
ml	O
(	O
3	O
.	O
3	O
nM	O
)	O
of	O
recombinant	O
human	B-OG
FSH	B-GP
(	O
Merck	O
Serono	O
,	O
Darmstadt	O
,	O
Germany	O
).	O

Cell	O
lysates	O
were	O
done	O
in	O
2	O
×	O
SDS	O
-	O
sample	O
buffer	O
(	O
pH	O
6	O
.	O
8	O
),	O
followed	O
by	O
boiling	O
.	O

Equivalent	O
amounts	O
of	O
proteins	O
were	O
separated	O
by	O
SDS	O
/	O
PAGE	O
on	O
Tris	O
-	O
glycine	O
polyacrylamide	O
gels	O
,	O
transferred	O
to	O
nitrocellulose	O
membranes	O
,	O
and	O
immunoblotted	O
with	O
rabbit	B-OG
polyclonal	O
antibodies	O
.	O

The	O
anti	O
-	O
phospho	O
(	O
T202	O
/	O
Y204	O
,	O
diluted	O
1	O
:	O
2	O
,	O
000	O
)	O
and	O
total	O
(	O
diluted	O
1	O
:	O
6	O
,	O
000	O
)	O
ERK	B-GP
1	I-GP
/	O
2	O
antibodies	O
were	O
from	O
Cell	O
Signaling	O
Technology	O
(	O
Beverly	O
,	O
MA	O
)	O
and	O
Santa	O
Cruz	O
(	O
Dallas	O
,	O
TX	O
),	O
respectively	O
.	O

Rabbit	B-OG
anti	O
-	O
phospho	O
-	O
MEK	B-GP
1	I-GP
/	O
2	O
(	O
S217	O
/	O
S221	O
,	O
diluted	O
1	O
:	O
1	O
,	O
000	O
)	O
and	O
mouse	B-OG
anti	O
-	O
total	O
MEK	B-GP
1	I-GP
/	O
2	O
(	O
diluted	O
1	O
:	O
2	O
,	O
000	O
)	O
antibodies	O
were	O
from	O
Cell	O
Signaling	O
Technology	O
(	O
Beverly	O
,	O
MA	O
).	O

Goat	B-OG
anti	O
-	O
rabbit	B-OG
IRDye	O
®	O
680	O
antibody	O
(	O
Licor	O
®,	O
Lincoln	O
,	O
NE	O
)	O
was	O
used	O
for	O
detection	O
with	O
an	O
Odyssey	O
®	O
CLx	O
scanner	O
(	O
Licor	O
®)	O
and	O
signals	O
were	O
quantified	O
using	O
Image	O
Studio	O
software	O
(	O
Licor	O
®).	O

Normalization	O
was	O
applied	O
as	O
ratio	O
of	O
phospho	O
ERK	B-GP
/	O
total	O
ERK	B-GP
signals	O
.	O

Data	O
were	O
analyzed	O
using	O
the	O
GraphPad	O
PRISM	O
software	O
and	O
differences	O
between	O
two	O
groups	O
were	O
assessed	O
by	O
a	O
two	O
-	O
tailed	O
paired	O
t	O
-	O
test	O
.	O

The	O
cut	O
-	O
off	O
for	O
significance	O
is	O
either	O
0	O
.	O
05	O
(⋆)	O
or	O
0	O
.	O
001	O
(⋆⋆).	O

Data	O
and	O
scripts	O

All	O
data	O
and	O
scripts	O
that	O
we	O
used	O
to	O
establish	O
the	O
results	O
presented	O
in	O
this	O
document	O
are	O
available	O
at	O
:	O
http	O
://	O
bios	O
.	O
tours	O
.	O
inra	O
.	O
fr	O
/	O
bios_group	O
/	O
sites	O
/	O
bios_group	O
/	O
IMG	O
/	O
zip	O
/	O
archive_article	O
.	O
zip	O
.	O

Electronic	O
supplementary	O
material	O

Supplementary	O
notes	O

Anne	O
Poupon	O
and	O
Christine	O
Froidevaux	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

Electronic	O
supplementary	O
material	O

Supplementary	O
information	O
accompanies	O
this	O
paper	O
at	O
10	O
.	O
1038	O
/	O
s41598	O
-	O
018	O
-	O
26006	O
-	O
2	O
.	O

Publisher	O
'	O
s	O
note	O
:	O
Springer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O

